Shire (SHPG) 10-Q 30 Oct 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - USD ($) shares in Millions, $ in Billions	9 Months Ended
	Sep. 30, 2015	Oct. 23, 2015	Jun. 30, 2015
Document and Entity Information [Abstract]
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Central Index Key	936,402
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Trading Symbol	SHP, SHPG
Entity Registrant Name	Shire plc
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	Yes
Entity Common Stock, Shares Outstanding		600.6
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Entity Public Float			$ 47.3

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 44.9	$ 2,982.4
Restricted cash	102	54.6
Accounts receivable, net	1,296	1,035.1
Inventories	608.9	544.8
Deferred tax asset	439.3	344.7
Prepaid expenses and other current assets	215	221.5
Total current assets	2,706.1	5,183.1
Non-current assets:
Investments	44.2	43.7
Property, plant and equipment, net ("PP&E")	795.9	837.5
Goodwill	4,289.6	2,474.9
Other intangible assets, net	9,450.6	4,934.4
Deferred tax asset	143.6	112.1
Other non-current assets	23.6	46.4
Total assets	17,453.6	13,632.1
Current liabilities:
Accounts payable and accrued expenses	2,001.8	1,909.4
Short-term borrowings	2,005.7	850
Other current liabilities	257	262.5
Total current liabilities	4,264.5	3,021.9
Non-current liabilities
Long-term borrowings	70.7	0
Deferred tax liability	2,824.8	1,210.6
Other non-current liabilities	739.8	736.7
Total liabilities	$ 7,899.8	$ 4,969.2
Commitments and contingencies
Equity:
Common stock of 5p par value; 1,000 million shares authorized; and 600.6 million shares issued and outstanding (2014: 1,000 million shares authorized; and 599.1 million shares issued and outstanding)	$ 58.9	$ 58.7
Additional paid-in capital	4,439.2	4,338
Treasury stock: 9.7 million shares (2014: 10.6 million shares)	(321.2)	(345.9)
Accumulated other comprehensive loss	(155.1)	(31.5)
Retained earnings	5,532	4,643.6
Total equity	9,553.8	8,662.9
Total liabilities and equity	$ 17,453.6	$ 13,632.1

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - £ / shares shares in Millions	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common Stock, Par Value (in GBP per share)	£ 0.05	£ 0.05
Common Stock, Shares Authorized	1,000	1,000
Common Stock, Shares, Issued	600.6	599.1
Common Stock, Shares, Outstanding	600.6	599.1
Treasury Stock, Shares	9.7	10.6

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues:
Product sales		$ 1,576.8	$ 1,552	$ 4,476.2	$ 4,329.7
Royalties		76.3	39.9	218.2	101.4
Other revenues		1.9	5.2	6.6	14.9
Total revenues		1,655	1,597.1	4,701	4,446
Costs and expenses:
Cost of product sales		262.7	254.3	718.5	760.8
Research and development	[1]	241.2	228.6	1,210.8	826
Selling, general and administrative	[1]	575	522.9	1,708.9	1,449.4
Gain on sale of product rights		(0.7)	(46)	(13)	(86.2)
Reorganization costs		31.1	28.2	59.6	123.4
Integration and acquisition costs		89.9	37.1	(46.8)	155.8
Total operating expenses		1,199.2	1,025.1	3,638	3,229.2
Operating income from continuing operations		455.8	572	1,063	1,216.8
Interest income		0.8	3.6	3.4	22.8
Interest expense		(10.7)	(6.8)	(31.6)	(25.7)
Other income, net		9.6	6.8	11.9	14.8
Total other (expense)/income, net		(0.3)	3.6	(16.3)	11.9
Income from continuing operations before income taxes and equity in (losses)/earnings of equity method investees		455.5	575.6	1,046.7	1,228.7
Income taxes		22.3	(61.2)	9	64.7
Equity in (losses)/earnings of equity method investees, net of taxes		(0.7)	1.4	(1.6)	3.8
Income from continuing operations, net of taxes		477.1	515.8	1,054.1	1,297.2
Loss from discontinued operations, net of taxes		(24.3)	(36.1)	(31.3)	(64)
Net income		$ 452.8	$ 479.7	$ 1,022.8	$ 1,233.2
Earnings Per Share, Basic [Abstract]
Earnings from continuing operations (in USD per share)		$ 0.807	$ 0.878	$ 1.786	$ 2.213
Loss from discontinued operations (in USD per share)		(0.041)	(0.061)	(0.053)	(0.109)
Earnings per ordinary share - basic (in USD per share)		0.766	0.817	1.733	2.104
Earnings Per Share, Diluted [Abstract]
Earnings from continuing operations (in USD per share)		0.804	0.870	1.777	2.191
Loss from discontinued operations (in USD per share)		(0.041)	(0.061)	(0.053)	(0.108)
Earnings per ordinary share - diluted (in USD per share)		0.763	0.809	1.724	2.083
Dividends per share declared		$ 0	$ 0	$ 0.1909	$ 0.1693
Weighted average number of shares:
Basic (in shares)	[2]	590.9	587.6	590.2	586.1
Diluted (in shares)		593.4	592.6	593.2	592.1
[1]	Research and development (“R&D”) includes IPR&D intangible asset impairment charges of $nil for the three months to September 30, 2015 (2014: $nil) and $523.3 million for the nine months to September 30, 2015 (2014: $188.0 million). Selling, general and administrative (“SG&A”) costs include amortization of intangible assets relating to intellectual property rights acquired of $132.7 million for the three months to September 30, 2015 (2014: $62.9 million) and $352.3 million for the nine months to September 30, 2015 (2014: $181.9 million).
[2]	Excludes shares purchased by the EBT and presented by Shire as treasury stock

Consolidated Statements of Inc5

Consolidated Statements of Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Intangible Assets (Excluding Goodwill) [Line Items]
Amortization of intangible assets			$ 352.3	$ 181.9
Impairment of unamortized intangible assets	$ 0	$ 0	523.3	188
Acquired Intellectual Property Rights
Intangible Assets (Excluding Goodwill) [Line Items]
Amortization of intangible assets	$ 132.7	$ 62.9	$ 352.3	$ 181.9

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Statement of Income and Comprehensive Income [Abstract]
Net income	$ 452.8	$ 479.7	$ 1,022.8	$ 1,233.2
Other comprehensive income:
Foreign currency translation adjustments	(41.6)	(86.1)	(124.9)	(75.9)
Unrealized holding (loss)/gain on available-for-sale securities (net of taxes of $nil, $3.4 million, $nil and $1.3 million)	(2)	(7.2)	1.3	(3.5)
Comprehensive income	409.2	$ 386.4	899.2	$ 1,153.8
Components of accumulated other comprehensive income
Foreign currency translation adjustments	(150.6)		(150.6)		$ (25.7)
Unrealized holding loss on available-for-sale securities, net of taxes	(4.5)		(4.5)		(5.8)
Accumulated other comprehensive loss	$ (155.1)		$ (155.1)		$ (31.5)

Consolidated Statements of Com7

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Statement of Income and Comprehensive Income [Abstract]
Unrealized holding (loss)/gain on available-for-sale securities, tax	$ 0	$ 3.4	$ 0	$ 1.3

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - 9 months ended Sep. 30, 2015 - USD ($) shares in Millions, $ in Millions		Total	Common stock	Additional paid-in capital	Treasury stock	Accumulated other comprehensive (loss)/income	Retained earnings
As at Dec. 31, 2014		$ 8,662.9	$ 58.7	$ 4,338	$ (345.9)	$ (31.5)	$ 4,643.6
Shares as at Dec. 31, 2014		599.1	599.1
Net income		$ 1,022.8					1,022.8
Other comprehensive loss, net of tax		(123.6)				(123.6)
Options exercised		0.2	$ 0.2
Option exercised (in shares)			1.5
Share-based compensation		70.8		70.8
Tax benefit associated with exercise of stock options (in US dollar)		30.4		30.4
Shares released by employee benefit trust to satisfy exercise of stock options		0.5			24.7		(24.2)
Dividends	[1]	(110.2)					(110.2)
As at Sep. 30, 2015		$ 9,553.8	$ 58.9	$ 4,439.2	$ (321.2)	$ (155.1)	$ 5,532
Shares as at Sep. 30, 2015		600.6	600.6
[1]	Dividends per share During the nine months to September 30, 2015 Shire plc declared and paid dividends of 19.09 US cents per ordinary share (equivalent to 57.27 US cents per ADS) totalling $110.2 million.

Consolidated Statements of Cha9

Consolidated Statements of Changes in Equity (Parenthetical) $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)$ / shares
Dividends per share declared	$ 0.1909
Dividends paid (in USD) | $	$ 110.2	[1]
Ordinary Shares
Dividends per share declared	$ 0.1909
Dividends per share paid	0.1909
ADS
Dividends per share declared	0.5727
Dividends per share paid	$ 0.5727
[1]	Dividends per share During the nine months to September 30, 2015 Shire plc declared and paid dividends of 19.09 US cents per ordinary share (equivalent to 57.27 US cents per ADS) totalling $110.2 million.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 1,022.8	$ 1,233.2
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	457.4	307.1
Share-based compensation	70.8	78.3
Change in fair value of contingent consideration	(196.5)	26.3
Impairment of intangible assets	523.3	188
Write down of assets	0	14
Gain on sale of product rights	(13)	(86.2)
Unwind of inventory fair value step-ups	23	90.6
Other, net	(3.8)	16.5
Movement in deferred taxes	(178.3)	63.1
Equity in losses/(earnings) of equity method investees	1.6	(3.8)
Changes in operating assets and liabilities:
Increase in accounts receivable	(288.1)	(92.1)
Iincrease in sales deduction accruals	100	28.2
Increase in inventory	(21.7)	(15.8)
Decrease/(increase) in prepayments and other assets	21.2	(114.7)
Increase/(decrease) in accounts and notes payable and other liabilities	56.5	(92.8)
Net cash provided by operating activities	1,575.2	1,673.5
CASH FLOWS FROM INVESTING ACTIVITIES:
Movements in restricted cash	(48)	(32.3)
Purchases of subsidiary undertakings and businesses, net of cash acquired	(5,553.4)	(4,104.4)
Purchases of non-current investments	(5.2)	(22.8)
Purchases of PP&E	(62.1)	(49.8)
Proceeds from short-term investments	67	57.8
Proceeds received on sale of product rights	14.5	122.7
Proceeds from disposal of non-current investments	18.5	21.3
Other, net	2.7	1.3
Net cash used in investing activities	(5,566)	(4,006.2)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long-term and short-term borrowings	3,650.8	2,310.8
Repayment of revolving line of credit and short term borrowings	(2,486.1)	(1,461.8)
Repayment of debt acquired through business combinations	0	(551.5)
Proceeds from ViroPharma call options	0	346.7
Payment of dividend	(110.2)	(99.6)
Excess tax benefit associated with exercise of stock options	30.5	37.4
Contingent consideration payments	(8.8)	(12.8)
Other, net	(21.3)	(2)
Net cash provided by financing activities	1,054.9	567.2
Effect of foreign exchange rate changes on cash and cash equivalents	(1.6)	(6.2)
Net decrease in cash and cash equivalents	(2,937.5)	(1,771.7)
Cash and cash equivalents at beginning of period	2,982.4	2,239.4
Cash and cash equivalents at end of period	44.9	467.7
Supplemental information associated with continuing operations:
Interest (paid)/received	(13.1)	8
Income taxes paid	(97.5)	(156.3)
Income taxes repaid	$ 77	232.6
Continung operations
Adjustments to reconcile net income to net cash provided by operating activities:
Gain on sale of product rights		(86.2)
Discontinued operations
Adjustments to reconcile net income to net cash provided by operating activities:
Gain on sale of product rights		33.6
Total
Adjustments to reconcile net income to net cash provided by operating activities:
Gain on sale of product rights		$ (52.6)

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies (a) Basis of preparation These interim financial statements of Shire plc and its subsidiaries (collectively “Shire” or the “Company”) and other financial information included in this Form 10-Q, are unaudited. They have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and US Securities and Exchange Commission (“SEC”) regulations for interim reporting. The balance sheet as at December 31, 201 4 was derived from audited financial statements but does not include all disclosures required by US GAAP. These interim financial statements should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company's Annual Report on Form 10-K for the year to December 31, 201 4 . Certain information and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period and the Company believes that the disclosures are adequate to make the information presented not misleading. Interim results are not necessarily indicative of results to be expected for the full year . (b) Use of estimates in interim financial statements The preparation of interim financial statements, in conformity with US GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of intangible assets, sales deductions, income taxes (including provisions for uncertain tax positions and the rea lization of deferred tax assets ), provisions for litigation and legal proceedings, contingent consideration receivable from product divestments and contingent consideration payable in respect of business combinations and asset purchases . If actual results differ from the Company's estimates, or to the extent these estimates are adjusted in future periods, the Company's results of operations could either benefit from, or be adversely affected by, any such change in estimate. (c ) New accounting pronouncements Adopted during the period Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity In April 2014 the Financial Accounting Standard s Board (“ FASB ”) issued guidance on the reporting of discontinued operations and disclosures of disposals of components of an entity. The amendments in this update revise the definition of discontinued operations by limiting discontinued operations reporting to disposals of components of an entity that represent strategic shifts that have (or will have) a major effect on an entity's operations and financial results. The guidance requires expanded disclosures for discontinued operations which provide users of financial statements with more information about the assets, liabilities, revenues, and expenses of discontinued operations. The guidance also requires an entity to disclose the pre-tax profit or loss of an individually significant component of an entity that does not qualify for discontinued operations reporting. Shire adopted this guidance in the period, which will be effective for discontinued operations occurring after January 1, 2015. The adoption of this guidance did not impact the Company's consolidated financial position, results of operations or cash flows . To be adopted in future periods Revenue from Contracts with Customers In May 2014 the FASB and the International Accounting Standards Board (together the “Accounting Standards Boards”) issued a new accounting standard that is intended to clarify and converge the financial reporting requirements for revenue from contracts with customers. The core principle of the standard is that an “entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services”. To achieve that core principle the Accounting Standard s Boards developed a five-step model (as presented below) and related application guidance, which will replace most existing revenue recognition guidance in US GAAP. Five-step model: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The Accounting Standards Boards also issued new qualitative and quantitative disclosure requirements as part of the new accounting standard which aims to enable financial statement users to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. In August 2015 the FASB decided to defer the effective date of the guidance by one year. Based on this deferral , public entities would need to apply the new guidance for annual reporting periods beginning after December 15, 2017, and interim periods therein. The Company is currently evaluating the impact of adopting this guidance . Amendments to the Consolidation Analysis In February 201 5 the FASB issued guidance to respond to stakeholders' concerns about the current accounting for consolidation of certain legal entities. Financial statement users asserted that in certain situations in which consolidation is ultimately required, deconsolidated financial statements are necessary to better analyze the reporting entity's economic and operational results. Previously, the FASB issued an indefinite deferral for certain entities to partially address those concerns. However, the amendments in this guidance rescind that deferral and address those concerns by making changes to the consolidation guidance. Under the amendments, all reporting entities are within the scope of Subtopic 810-10, Consolidation , including limited partnerships and similar legal entities, unless a scope exception applies. The presumption that a general partner controls a limited partnership has been eliminated. In addition, fees paid to decision makers that meet certain conditions no longer cause decision makers to consolidate a VIE in certain instances. The amendments place more emphasis in the consolidation evaluation on variable interests other than fee arrangements such as principal investment risk (for example, debt or equity interests), guarantees of the value of the assets or liabilities of the VIE, written put options on the assets of the VIE, or similar obligations, including some liquidity commitments or agreements (explicit or implicit). Additionally, the amendments reduce the extent to which related party arrangements cause an entity to be considered a primary beneficiary. The amendments are effective for public business entities for fiscal years, and for interim periods therein, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. The Company does not expect the adoption of this guidance to have a material effect on its consolidated financial position, results of operations and cash flows. Simplify ing the Presentation of Debt Issuance Costs In April 201 5 the FASB issued guidance to simplify the presentation of debt issuance costs . The guidance require s that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this u pdate. In August 2015 the FASB issued further guidance to incorporate the SEC staff's observation that , given the absence of authoritative guidance , the SEC staff would not object to an entity deferring and presenting debt issuance costs arising from line-of-credit arrangements as an asset and subsequently amortizing these costs ratably over the term of the line-of-credit arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. T he amendments in these updates are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods therein. Early adoption is permitted for financial statements that have not been previously issued. An entity should apply the new guidance on a retrospective basis, wherein the balance sheet of each individual period presented should be adjusted to reflect the period-specific effects of applying the new guidance. Upon transition, an entity is required to comply with the applicable disclosures for a change in an accounting principle. The Company does not expect the adoption of this guidance to have a material effect on its consolidated financial position, results of operations and cash flows . Customer's Accounting for Fees Paid in a Cloud Computing Arrangement In April 2015 the FASB issued guidance to simplify the customer's accounting for fees paid in a cloud computing arrangement. The amendments provide guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The amendments will be effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted for all entities. An entity can elect to adopt the guidance either a) prospectively to all arrangements entered into or materially modified after the effective date or b) retrospectively. The Company is currently evaluating the impact of adopting this guidance . Simplifying the Measurement of Inventory In July 2015 the FASB issued guidance to simplify the measurement of i nventory which currently requires an entity to measure its inventory at the lower of cost or market, whereby market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. The amendment provide s guidance that an entity should measure inventory within the scope of this u pdate at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using l ast in first out or the retail inventory method. Th is amendment will be effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2016. Early adoption is permitted for all entities. The Company is currently evaluating the impact of adopting this guidance . Simplifying the Accounting for Measurement-Period Adjustments In September 2015 the FASB issued guidance to simplify the accounting for measurement -period adjustment. The amendments in this update require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The guidance further requires that the acquirer record, in the same period's financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date and present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. The guidance will be effective for fiscal year beginning after December 15, 2015, including interim periods within those fiscal years. The guidance should be applied prospectively to adjustments to provisional amounts that occur after the effective date of this update with earlier application permitted for financial statements that have not been issued.

Business Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Business Combination Disclosure	2 . Business c ombinations Acquisition of NPS Pharma On February 21, 201 5 Shire completed its acqui sition of 100% of the outstanding share capital of NPS Pharma. The acquisition-date fair value of cash consideration paid on closing was $ 5 , 220 million. The acquisition of NPS Pharma added GATTEX/REVESTIVE, approved in the US and EU for the treatment of adults with short bowel syndrome (“SBS”), a rare and potentially fatal gastrointestinal disorder and NATPARA/NATPAR approved in the US for the treatment of hypoparathyroidism (“HPT”), a rare endocrine disease, to Shire's portfolio of currently marketed products . The acquisition of NPS Pharma has been accounted for as a business combination using the acquisition method . The assets acquired and the liabilities assumed from NPS Pharma have be en recorded at their preliminary fair value s at the date of acquisition , being February 21, 2015 . The Company 's consolidated financial statements include the results of NPS Pharma from February 21, 2015 . The amount of NPS Pharma 's post-acquisition revenues and pre-tax losses included in the Company's consolidated statement of income for the three months to September 30, 2015 were $ 86.7 million and $ 47.5 million respectively. The pre-tax loss includes charges relating to the unwind of inventory fair value adjustments of $ 6.7 million, intangible asset amortization of $ 70.9 million and integration costs of $ 16.2 million. The amount of NPS Pharma 's post-acquisition revenues and pre-tax losses included in the Company's consolidated statement of income for the nine months to September 30, 2015 were $ 193.8 million and $ 207.4 million respectively. The pre-tax loss includes charges on the unwind of inventory fair value adjustments of $ 21.7 million, intangible asset amortization of $ 172.4 million and integration costs of $ 76.9 million. The Company's preliminary allocation of the purchase price to the assets acquire d and liabilities assumed , including certain immaterial measurement period adjustments recorded in the second quarter of 2015 , is outlined below : Preliminary Fair value $’M ASSETS Current assets: Cash and cash equivalents 41.6 Short-term investments 67.0 Accounts receivable 33.4 Inventories 89.4 Deferred tax assets 156.3 Other current assets 11.1 _______________ Total current assets 398.8 Non-current assets: PP&E 4.8 Goodwill 1,679.4 Other intangible assets - currently marketed products 4,640.0 - royalty rights (categorized as "Other amortized intangible assets" ) 353.0 _______________ Total assets 7,076.0 _______________ LIABILITIES Current liabilities: Accounts payable and other current liabilities 72.5 Short-term debt 27.4 Non-current liabilities: Long-term debt, less current portion 78.9 Deferred tax liabilities 1,673.1 Other non-current liabilities 4.5 _______________ Total liabilities 1,856.4 _______________ Fair value of identifiable assets acquired and liabilities assumed 5,219.6 Consideration _______________ Cash consideration paid 5,219.6 _______________ The purchase price allocation is preliminary pending final determination of the fair values of certain assets and liabilities. In particular the fair values of intangible assets and current and deferred tax assets and liabilities are preliminary pending receipt of the final valuations for those items. The final determination of these fair values will be completed as soon as possible but no later than one year from the acquisition date . (a) Other intangible assets – currently marketed products Other intangible assets totaling $ 4,640 .0 million relate to intellectual property rights acquired for NPS Pharma's currently marketed products, primarily attributed to NATPARA/NATPAR and GATTEX/REVESTIVE. The fair value of the currently marketed products is preliminary and has been estimated using an income approach, based on the present value of incremental after tax cash flows attributable to each separately identifiable intangible asset. The estimated useful lives of the NATPARA/NATPAR and GATTEX/REVESTIVE intangible assets are 24 years, with amortization being recorded on a straight-line basis. (b) Other intangible assets – Royalty rights Other intangibles totaling $ 353.0 million relate to the royalty rights arising from the collaboration agreements with Amgen, Janssen and Kyowa Hakko Kirin. Amgen markets cinacalcet HCl as Sensipar in the US and as Mimpara in the EU; Janssen Pharmaceuticals markets tapentadol as Nucynta in the US; and Kyowa Hakko Kirin markets cinacalcet HCI as Regpara in Japan, Hong Kong, Malaysia, Macau, Singapore, and Taiwan. NPS Pharma is entitled to royalties from the relevant net sales of these products. The fair value of these royalty rights is preliminary and has been estimated using an income approach, based on the present value of incremental after tax cash flows attributable to each royalty right. The estimated useful lives of these royalty rights range from 4 to 5 years (weighted average 4 years), with amortization being recorded on a straight-line basis. (c) Goodwill Goodwill arising of $ 1,6 79 .4 million, which is not deductible for tax purposes, includes the expected synergies that will result from combin ing the operations of NPS Pharma with the operations of Shire , particularly those synergies expected to be realized due to Shire's structure ; intangible assets that do not qualify for separate recognition at the time of the acquisition; and the value of the assembled workforce. In the three and nine months to September 30 , 2015 the Company expensed costs of $ 13.6 million and $ 131 .2 million respectively, relating to the acquisition and post-acquisition integration of NPS Pharma , which have been recorded within I ntegration and acquisition costs in the Company's consolidated statement of income . Supplemental disclosure of pro forma information The following unaudited pro forma financial information presents the combined results of the operations of Shire and NPS Pharma as if the acquisition of NPS Pharma had occurred as at January 1, 2014. The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations actually would have been had the acquisition been completed at the date indicated. In addition, the unaudited pro forma financial information does not purport to project the future results of operations of the combined Company. 9 months to 9 months to September 30, September 30, 2015 2014 $’M $’M _______________ _______________ Revenues 4,730.9 4,603.4 Net income from continuing operations 1,005.6 1,028.8 _______________ _______________ Per share amounts: Net income from continuing operations per share - basic 170.4c 175.5c Net income from continuing operations per share - diluted 169.5c 173.8c _______________ _______________ The unaudited pro forma financial information above reflects the following pro forma adjustments: an adjustment to decrease net income by $ 105.2 million for the period to September 30, 2014 to reflect acquisition costs incurred by Shire and NPS Pharma, and increase net income by $105 .2 million for the period to September 30, 2015 to eliminate acquisition costs incurred ; an adjustment to decrease net income by $ 13.4 million for the period to September 30, 2014 to reflect charges on the unwind of inventory fair value adjustments as acquisition date inventory is sold, and a corresponding increase in net income for the period to September 30, 2015; an adjustment of $ 16.7 million in the period to September 30 , 2014 to reflect additional interest expense associated with the drawdown of debt to partially finance the acquisition of NPS Pharma and the amortization of related deferred debt issuance costs ; and an adjustment to increase amortizatio n expense by approximately $21.2 million in the period to September 30 , 2015 and $ 12 6.5 million in the period to September 30 , 2014 related to amortization of the fair value of identifiable intangible assets acquired and the elimination of NPS Pharma's historical intangible asset amortization expense . T he adjustments above are stated net of their tax effects , where applicable. Acquisition of Foresight Biotherapeutics , Inc. (“Foresight”) On July 30, 2015 Shire completed the acquisition of 100% of the outstanding share capital of Foresight, a privately owned company incorporated in New York. The acquisition-date fair value of cash consideration, which was paid on closing, was $298.8 million. With this acquisition, Shire acquire d the global rights to SHP640 (formerly FST-100 ) , a Phase-3 ready therapy for the treatment of infectious conjunctivitis, an ocular surface condition commonly referred to as pink eye. The acquisition of Foresight has been accounted for as a business combination using the acquisition method. The assets and liabilities acquired from Foresight have been recorded at their preliminary fair values at the date of acquisition, being July 30, 2015. The Company's consolidated financial statements include the results of Foresight from July 30, 2015. The purchase price allocation is preliminary pending the determination of the fair values of certain assets and liabilities. The purchase price has been allocated on a preliminary basis to the SHP640 IPR&D intangible asset ($300.0 million), net current assets assumed ($3.0 million), net non-current liabilities assumed (including deferred tax liabilities) ($116.3 million) and goodwill ($112.1 million). Goodwill is not deductible for tax purposes. Unaudited pro forma financial information to present the combined results of operations of Shire and Foresight is not provided as the impact of this acquisition is not material to the Company's results of operations for any period presented . Acquisition of Solpharm d.o.o (“ Solpharm ”) On September 28, 2015 Shire completed the acquisition of 100% of the outstanding share capital of Solpharm , a privately-owned company incorporated in Croatia. The acquisition-date fair value of consideration was $5.2 million, comprising cash paid on closing of $4.5 million and the fair value of contingent consideration payable of $0.7 million (maximum payable $3.1 million dependent upon achievement of post-closing milestones). Shire has preliminarily allocated the purchase price to goodwill ($4.4 million) and other net assets ($0.8 million). Unaudited pro forma financial information to present the combined results of operations of Shire and Solpharm is not provided as the impact of this acquisition is not material to the Company's results of operations for any period presented . Acquisition of Meritage Pharma Inc. (“ Meritage ”) Prior to the acquisition of ViroPharma Incorporated (“ ViroPharma ”) by Shire (see below) , ViroPharma had entered into an exclusive development and option agreement with Meritage , a privately owned US company focusing on developing oral budesonide suspension (“OBS”) as a treatment for eosinophilic esophagitis. Under the terms of this agreement Meritage controlled and conducted all related research up to achievement of pre-defined development success criteria at which point ViroPharma had the option to acquire Meritage . On February 18, 2015 , following the exercise of the purchase option, Shire acquired all the outstan ding equity of Meritage . The acquisition date fair value of the consideration totalled $166.9 million, comprising cash consideration paid on closing of $74.8 million and the fair value of contingent consideration payable of $92.1 million. The maximum amount of contingent cash consideration which may be payable by Shire in future periods is $175.0 million dependent upon achievement of certain clinical development and regulatory milestones. With the Meritage acquisition, Shire has acquired the global rights to Meritage's Phase 3-ready compound , OBS (now SHP621) , for the treatment of adolescents and adults with eosinophilic esophagitis . The acquisition of Meritage has been accounted for as a business combination using the acquisition method. The assets and liabilities assumed from Meritage have been recorded at their preliminary fair values at the date of acquisition, being February 18, 2015. The Company's consolidated financial statements and results of operations include the results of Meritage from February 18, 2015. The purchase price allocation is preliminary pending the determination of the fair values of certain assets and liabilities. The purchase price has been allocated on a preliminary basis to the SHP621 IPR&D intangible asset ($175 million), net current assets assumed ($5.5 million), net non-current liabilities assumed (including deferred tax liabilities) ($54.7 million) and goodwil l ($41.1 mil lion). Goodwill arising of $41.1 million is not deductible for tax purposes. Unaudited pro forma financial information to present the combined results of operations of Shire and Meritage is not provided as the impact of this acquisition is not material to the Company's results of operations for any period presented . Acquisition of ViroPharma On January 24, 2014 Shire completed its acquisition of 100% of the outstanding share capital of ViroPharma . The acquisition-date fair value of cash consideration paid on closing was $3,997 million. The acquisition of ViroPharma added CINRYZE to Shire's portfolio of currently marketed products. CINRYZE is a leading brand for the prophylactic treatment of Hereditary Angioedema (“HAE”) in adolescents and adults. The acquisition of ViroPharma has been accounted for as a business combination using the acquisition method. The assets acquired and the liabilities assumed from ViroPharma have been recorded at their fair values at the date of acquisition, being January 24, 2014. The Company's consolidated financial statements include the results of ViroPharma from January 24, 2014 . The purchase price allocation was finalized in the fourth quarter of 2014. The Company's allocation of the purchase price to the fair value of assets acquired and liabilities assumed is outlined below: Acquisition date fair value $’M Identifiable assets acquired and liabilities assumed ASSETS Current assets: Cash and cash equivalents 232.6 Short-term investments 57.8 Accounts receivable 52.2 Inventories 203.6 Deferred tax assets 100.7 Purchased call option 346.7 Other current assets 50.9 _______________ Total current assets 1,044.5 Non-current assets: PP&E 24.7 Goodwill 1,655.5 Other intangible assets - Currently marketed products 2,320.0 - In-Process Research and Development (“IPR&D”) 315.0 Other non-current assets 10.4 _______________ Total assets 5,370.1 _______________ LIABILITIES Current liabilities: Accounts payable and other current liabilities 122.7 Convertible bond 551.4 Non-current liabilities: Deferred tax liabilities 603.5 Other non-current liabilities 95.5 _______________ Total liabilities 1,373.1 _______________ Fair value of identifiable assets acquired and liabilities assumed 3,997.0 _______________ Consideration Cash consideration paid 3,997.0 _______________ (a) Other intangible assets – currently marketed products Other intangible assets totaled $2,320.0 million at the date of acquisition, relat ing to intellectual property rights acquired for ViroPharma's then currently marketed products, primarily attributed to CINRYZE, for the routine prophylaxis against HAE attacks in adolescent and adult patients. Shire also obtained intellectual property rights to three other commercialized products, PLENADREN, an orphan drug for the treatment of adrenal insufficiency in adults, BUCCOLAM, an oromucosal solution for the treatment of prolonged, acute, and convulsive seizures in infants, toddlers, children and adolescents and VANCOCIN, an oral capsule formulation for the treatment of C. difficile-associated diarrhea (“CDAD”) , which was divested by Shire in the t hird quarter of 2014 . The fair value of currently marketed products has been estimated using an income approach, based on the present value of incremental after tax cash flows attributable to each separately identifiable intangible asset. The estimated useful lives of the CINRYZE, PLENADREN and BUCCOLAM intangible assets range from 10 to 23 years (weighted average 22 years), with amortization bein g recorded on a straight- line basis. (b) Other intangible assets – IPR&D The IPR&D asset of $315.0 million relates to m aribavir (now SHP620) , an investigational antiviral product for cytomegalovirus. The fair value of this IPR&D asset was estimated based on an income approach, using the present value of incremental after tax cash flows expected to be generated by this development project after the deduction of contributory asset charges for other assets employed in this project . The estimated cash flows have been probability adj usted to take into account the stage of completion and the remaining risks and uncertainties surrounding the future development and commercialization. The major risks and uncertainties associated with the timely completio n of the acquired IPR&D project include the ability to confirm the efficacy of the technology based on the data from clinical trials, and obtaining the relevant regulatory approvals as well as other risks as described in the Company's A nnual R eport on Form 10-K. The valuation of IPR&D has been based on information available at the time of the acquisition (and information obtained during the measurement period) and on expectations and assumptions that (i) have been deemed reasonable by the Company's management and (ii) are based on information, expectations and assumptions that would be available to a market participant. However, no assurance can be given that the assumptions and events associated with such assets will occur as projected. For these reasons, the actual cash flows may vary from forecast future cash flows. The estimated probability adjusted after tax cash flows used in fair valuing other intangible assets have been discounted at rates ranging from 9.5% to 10.0%. (c) Goodwill Goodwill arising of $1, 655.5 million, which is not deductible for tax purposes, includes the expected operational synergies that will result from combining the commercial operations of ViroPharma with th ose of Shire (valued at approximately $ 400 m illion) ; other synergies expected to be realized due to Shire's structure; intangible assets that do not qualify for separate recognition at the time of the acquisition; and the value of the assembled workforce .

Reorganization Costs

Reorganization Costs	9 Months Ended
	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
Reorganization Costs Disclosure	3 . Reorganization costs One Shire business re organization On May 2, 2013, the Company initiated the reorganization of its business to integrate the three divisions into a simplified One Shire organization in order to drive future growth and innovation. In 2014 c ertain aspects of the One Shire program were temporarily put on hold due to AbbVie's offer for Shire, which was terminated in October 2014. Subsequent to the termination of AbbVie's offer, Shire announced on November 10, 2014 its plans to relocate over 500 positions to Lexington , Massachusetts from its Chesterbrook , Pennsylvania, site and establish Lexington as the Company's US operational headquarters in continuation of the One Shire efficiency program. This relocation will streamline business globally through two principal locations, Massachusetts and Switzerland, with support from regional and country-based offices around the world. In the three and nine months to September 3 0 , 201 5 the Company incurred reorganization costs totaling $ 31. 1 million and $ 59. 6 million respectively , relating to employee involuntary termination benefits and other reorganization costs. Reorganization costs of $ 305. 1 million have been incurred since May 2013. The One Shire reorganization is expected to be substantially completed by the end of 201 5 . Currently, the Company estimates that further costs in respect of the One Shire reorganization of approximately $ 85 million will be expensed as incurred. The liability for reorganization costs arising from the One Shire business reorganization at September 3 0 , 201 5 is as follows : Opening liability Amount Closing liability at at January 1, charged to re- September 30, 2015 organization Paid/Utilized 2015 $'M $'M $'M $'M ___________ ____________ ___________ ___________ Involuntary termination benefits 38.0 38.5 (53.7) 22.8 Other reorganization costs - 21.1 (10.4) 10.7 ___________ ___________ ___________ ___________ 38.0 59.6 (64.1) 33.5 ___________ ___________ ___________ ___________ At September 30, 2015 the closing reorganization cost liability was recorded within accounts payable and accrued expenses .

Integration and acquisition cos

Integration and acquisition costs	9 Months Ended
	Sep. 30, 2015
IntegrationAndAcquisitionCosts[Abstract]
Integration and acquisition costs	4 . Integration and a cquisition costs For the three months to September 30, 2015 integration and acquisition costs of $89.9 million principally comprise costs related to the acquisition and integration of NPS Pharma , Viropharma and the proposed combination with Baxalta ($ 30.7 million) and charges related to the change in the fair value of contingent consideration liabilities ($59. 2 million) principally in relation to the acquisition of Lumena Pharmaceuticals, Inc. (“ Lumena ”), following the agreement to settle all future contingent milestones payable to former Lumena shareholders through a one- time $90 million payment. For the nine months to September 30, 2015 Shire recorded a net credit to integration and acquisition costs of $ 46.8 million. The net credit principally comprises costs related to the acquisition and integration of NPS Pharma , Viropharma and the proposed combination with Baxalta ($ 149.7 million), offset by a net credit relating to the change in the fair value of contingent conside ration liabilities ($ 196.5 million). The net credit relating to the change in fair value of contingent consideration liabilities in the nine months to September 30, 2015 principally relates to the acquisition of Lumena , reflecting ( i ) a lower probability of success for the SHP625 asset following the receipt of data from certain Phase 2 studies and (ii) the aforementioned agreement in the third quarter of 2015 to settle all future contingent milestones payable to former Lumena shareholders, and the acquisition of Lotus Tissue Repair, Inc. reflecting a lower probability of success for the SHP608 asset (for the treatment of Dystrophic Epidermolysis Bullosa (“DEB”)) as a result of certain preclinical toxicity findings (see note 10 for further details) . In the three and nine months to September 30, 2014 Shire recorded integration and acquisition costs of $ 37.1 million and $155.8 million respectively. In the three months to September 30, 2014 the charge comprised a $4.9 million net charge on the change in fair value of contingent consideration liabilities and $32.2 million relating to the acquisition and integration of ViroPharma . In the nine months to September 30, 2014 the charge comprised $129.5 million relating to the acquisition and integration of ViroPharma and a net charge of $26.3 million relating to the change in fair value of contingent consideration liabilities (principally in relation to the acquisition of SARcode Bioscience Inc. (“ SARcode ”), reflecting Shire's increased confidence in the SHP606 asset, offset by credits in relation to the acquisition of FerroKin BioSciences , Inc., reflecting the decision to place the Phase 2 clinical trial for SHP602 on clinical hold) .

Accounts Receivable, Net

Accounts Receivable, Net	9 Months Ended
	Sep. 30, 2015
Receivables [Abstract]
Accounts Receivable Disclosure	5. Accounts receivable, net Accounts receivable at September 30 , 2015 of $1,296.0 million ( December 31, 2014: $ 1,035.1 million) , are stated net of a provision for disco unts and doubtful accounts of $55.7 million (December 31 , 2014 : $48.5 million ) . Provision for discounts and doubtful accounts: 2015 2014 $’M $’M _____________ _____________ As at January 1, 48.5 47.9 Provision charged to operations 293.8 228.1 Provision utilization (286.6) (229.8) _____________ _____________ As at September 30, 55.7 46.2 _____________ _____________ At September 30 , 2015 accounts receivable included $ 71.4 million (December 31, 2014: $ 59 . 0 million) related to royalty income .

Inventories

Inventories	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure	6. Inventories I nventories are stated at the lower of cost or market. Inventories comprise : September 30, December 31, 2015 2014 $’M $’M ____________ ____________ Finished goods 161.0 136.0 Work-in-progress 334.9 305.3 Raw materials 113.0 103.5 ____________ ____________ 608.9 544.8 ____________ ____________

Results of discontinued operati

Results of discontinued operations	9 Months Ended
	Sep. 30, 2015
DiscontinuedOperationsAndDisposalGroupsAbstract
Results of discontinued operations Disclosure	7 . Results of discontinued operations Following the divestment of the Company's DERMAGRAFT business in January 2014, the operating results associated with the DERMAGRAFT business have been classified as discontinued operations in the consolidated statements of income for all periods presented. In the three and nine months to September 30, 2015 the Company recorded a loss, net of tax of $ 24.3 million and $ 31.3 million respectively, primarily relating to a change in estimate in relation to reserves for onerous leases retained by the Company. In the three and nine months to September 30, 2014 the Company recorded a loss, net of tax of $36.1 million and $64.0 million, primarily relating to costs associated with the divestment including a loss on re-measuring to fair value the contingent consideration receivable from Organogen e sis.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2015
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expense and Other Assets, Current	8 . Prepaid expenses and other current assets September 30, December 31, 2015 2014 $’M $’M ______________ ____________ Prepaid expenses 50.6 36.9 Income tax receivable 96.5 121.5 Value added taxes receivable 18.8 13.8 Other current assets 49.1 49.3 ______________ ______________ 215.0 221.5 ______________ ______________

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill Disclosure	9 . Goodwill September 30, December 31, 2015 2014 $’M $’M ____________ ____________ Goodwill arising on businesses acquired 4,289.6 2,474.9 ____________ ____________ In the nine months to September 3 0 , 201 5 the Company completed the acquisition s of NPS Pharma , Meritage , Foresight and Solpharm which resulted in aggregate goodwill with a preliminary value of $ 1, 83 7 million (see Note 2 for details ) . 2015 2014 $’M $’M ____________ ____________ As at January 1, 2,474.9 624.6 Acquisitions 1,837.0 1,773.8 Foreign currency translation (22.3) (24.7) ____________ ____________ As at September 30, 4,289.6 2,373.7 ____________ ____________

Other Intangible Assets, Net

Other Intangible Assets, Net	9 Months Ended
	Sep. 30, 2015
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Other Intangible Assets Disclosure	10 . Other intangible assets, net September 30, December 31, 2015 2014 $’M $’M ________________ ________________ Amortized intangible assets Intellectual property rights acquired for currently marketed products 9,388.5 4,816.9 Other intangible assets 1 375.0 30.0 ________________ ________________ 9,763.5 4,846.9 Unamortized intangible assets Intellectual property rights acquired for IPR&D 1,482.4 1,550.0 ________________ ________________ 11,245.9 6,396.9 Less: Accumulated amortization 2 (1,795.3) (1,462.5) ________________ ________________ 9,450.6 4,934.4 ________________ ________________ Other intangible assets primarily comprises of royalty right assets acquired with NPS Pharma. Comprising $ 1,734.9 million of accumulated amortization for intellectual property rights acquired for currently marketed products and $ 60.4 million for other intangible assets . The change in the net book value of other intangible assets for the nine months to September 30 , 2015 and 201 4 is shown in the table below: Other intangible assets 2015 2014 $’M $’M ________________ ________________ As at January 1, 4,934.4 2,312.6 Acquisitions 5,473.7 3,332.8 Divestment of non-core products - (17.3) Amortization charged (352.3) (181.9) Impairment charges (523.3) (188.0) Foreign currency translation (81.9) (30.8) ________________ ________________ As at September 30, 9,450.6 5,227.4 ________________ ________________ In the nine months to September 30, 2015 the Company acquired intangible assets totaling $ 5, 47 4 million, primarily relating to the fair value of intangible assets for currently marketed products and royalty right assets acquired with NPS Pharma of $ 4 , 99 3 million and IPR&D assets of $ 4 75 million acquired with Meritage and Foresight (see Note 2 for further details). The Company reviews its intangible assets for impairment whenever events or circumstances suggest that their carrying value may not be recoverable. In the nine months to September 30, 2015 the Company identified indicators of impairment in respect of its SHP625 ( for the treatment of cholestatic liver disease ), and SHP608 ( for the treatment of DEB ) IPR&D assets . The indicators of impairment related to SHP625 in the second quarter of 2015 included the results of three Phase 2 studies, comprising a 13-week study of 20 paediatric patients with Alagille syndrome (“ALGS”), a 13 week, double blind, placebo-controlled trial in combination with ursodeoxycholic acid (“ UD CA”) for patients with Primary Biliary Cirrhosis (“PBC”), and preliminary results from a 72 week open label Phase 2 study in Progressive Familial Intrahepatic Cholestasis (“PFIC”). Although both the ALGS and PBC trials indicated a reduction in bile serum acids in the SHP625 treated group, neither of these trials met their primary or secondary endpoints. The interim analysis in the PFIC trial was based on the first 12 subjects who completed 13 weeks of treatment per protocol. There was no statistically significant reduction in mean serum bile acid levels from baseline . A change from baseline analysis was planned as there is no placebo treatment arm in this study. However, changes from baseline for pruritus did reach statistical significance. Following these trial results, the Company reviewed the recoverability of its SHP625 IPR&D asset in the second quarter of 2015 and recorded an impairment charge of $346.6 million (within R&D expenses in the consolidated statement of income) to record the SHP625 IPR&D asset to its revised fair value of $120.4 million. This fair value was based on the revised discounted cash flow forecasts associated with SHP625 , which included a reduced probability of achieving regulatory approval. For SHP608, preclinical toxicity findings in the second quarter of 2015 have led to a significant reduction in the probability of achieving regulatory approval of this asset. As a result, the Company recorded an impairment charge of $ 176.7 million within R&D expenses in the consolidated statement of income to fully write off the SHP608 IPR&D asset. The fair values of the related contingent consideration liabilities arising from the Lumena and Lotus Tissue Repair acquisitions (through which Shire acquired SHP625 and SHP608 respectively) have also been reduced, resulting in a credit of $2 0 3 . 4 million being recorded in Integration and acquisition costs for the nine months ended September 30, 2015. In the nine months to September 30, 2014 the Company identified indicators of impairment in respect of its SHP602 ( iron chelating agent for the treatment of iron overload secondary to chronic transfusion ) and SHP613 ( for the treatment of improvement in patency of arteriovenous access in hemodialysis patients) IPR&D asset s . The Company therefore reviewed the recoverability of its SHP602 and SHP613 IPR&D assets and recorded an impairment charge of $166.0 million and $22.0 million, respectively , within R&D expenses in the consolidated statement of income to record the IPR&D assets to their revised fair value . Management estimates that the annual amortization charge in respect of intangible assets held at September 30, 2015 will be approximately $ 470 million for each of the five years to September 30 , 20 20 . Estimated amortization expense can be affected by various factors including future acquisitions, disposals of product rights, regulatory approval and subsequent amortization of acquired IPR&D projects, foreign exchange movements and the technological advancement and regulatory approval of competitor products.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2015
Accounts Payable and Accrued Liabilities, Current [Abstract]
Accounts Payable and Accrued Expenses Disclosure	11 . Accounts payable and accrued expenses September 30, December 31, 2015 2014 $’M $’M ________________ ________________ Trade accounts payable and accrued purchases 313.2 247.7 Accrued rebates – Medicaid 636.4 563.9 Accrued rebates – Managed care 336.5 318.2 Sales return reserve 141.8 131.7 Accrued bonuses 133.7 150.7 Accrued employee compensation and benefits payable 118.9 109.1 R&D accruals 71.5 88.3 Other accrued expenses 249.8 299.8 ________________ ________________ 2,001.8 1,909.4 ________________ ________________

Other Current Liabilities

Other Current Liabilities	9 Months Ended
	Sep. 30, 2015
Other Liabilities, Current [Abstract]
Other Current Liabilities	12 . Other current liabilities September 30, December 31, 2015 2014 $’M $’M _____________ _____________ Income taxes payable 76.0 16.2 Value added taxes 21.6 16.6 Contingent consideration payable 111.7 194.5 Other current liabilities 47.7 35.2 _____________ _____________ 257.0 262.5 _____________ _____________

Borrowings

Borrowings	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Borrowings Disclosure	13 . Borrowings September 30, December 31, 2015 2014 $’M $’M _____________ _____________ Short term borrowings: Borrowings under the 2015 Facility Agreement 750.0 - Borrowings under the 2013 Facilities Agreement - 850.0 Borrowings under the RCF 1,245.0 - Secured non-recourse debts 10.7 - _____________ _____________ 2,005.7 850.0 Long term borrowings: Secured non-recourse debts 70.7 - _____________ _____________ 2,076.4 850.0 _____________ _____________ Term Loan Agreement s 2015 Facilit y Agreement On January 11, 2015, Shire entered into a n $850 million Facility Agreement with, among others, Citi Group Global Markets Limited (acting as mandated lead arranger and bookrunner ) (the “2015 Facilit y Agreement”). On September 28, 2015 the Company reduced the 2015 Facility Agreement by $100 million. At September 30, 2015 t he 2015 Facilit y Agreement, which matures on January 10, 2016 , was fully utilized in the amount of $750 million. The maturity date may be extended twice, at Shire's option, by six months on each occasion. T he 2015 Facilit y Agreement has been used to partially finance the purchase price payable in respect of Shire's acquisition of NPS Pharma (including certain related costs). See the Company's 2014 Annual Report on Form 10-K for details of the 2015 Facility Agreement . 2013 Facilities Agreement On November 11, 2013, Shire entered into a $2 , 60 0 million f acilities a greement with, among others, Morgan Stanley Bank International Limited (acting as mandated lead arranger and bookrunner ) (the “ 2013 Facilities Agreement”). The 2013 Facilities Agreement comprise d two credit facilities: ( i ) a $1 , 75 0 million term loan facility and (ii) a n $ 850 million term loan facility. On December 13, 2013 and at various points thereafter , the Company cancelled part s of the 2013 Facilities Agreement . On September 28, 2015 the Company repaid in full the remaining balance of $350 million under the 2013 Facilities Agreement . Revolving Credit Facility (“RCF”) On December 12, 2014, Shire entered into a $2,100 million RCF with a number of financial institutions . See the Company's 2014 Annual Report on Form 10-K for details. At September 3 0 , 201 5 the Company has utilized $ 1,245 million of the RCF. The RCF, which terminates on December 12, 2019, may be applied towards financing the general corporate purposes of Shire. The RCF incorporates a $250 million US dollar and euro swingline facility operating as a sub-limit thereof . Secured N on-recourse D ebt s Prior to the acquisition by Shire, NPS Pharma had: partially monetized rights to receive future royalty payments from Amgen's sales of SENSIPAR and MIMPARA through the issuance of $145 million of non-recourse debt that wa s both serviced and secured by SENSIPAR and MIMPARA royalty revenue; sold to DRI Capital Inc. (“DRI”) certain rights to receive up to $96 million of future royalty payments arising from Kyowa Hakko Kirin's sales of REGPARA and granted DRI a security interest in the license agreement with Kyowa Hakko Kirin, certain patents and other intellectual property related to REGPARA which DRI would be entitled to enforc e in the event of default by NPS Pharma ; and partially monetized PTH-184 (now marketed as NATPARA) through an agreement with an affiliate of DRI pursuant to which NPS Pharma, its license e s and its predecessors in interest, are obligated to pay up to $125 million royalties on sales of PTH-184. Additionally, NPS Pharma granted DRI a security interest in certain patents and other intellectual property related to PTH 1-84 which DRI would be entitled to enforc e in the event of default by NPS Pharma. Following the acquisition of NPS Pharma the Company has assumed these secured non-recourse debt obl igations. In May 2015 the Company notified Amgen that it intended to repay in full the remaining non-recourse debt owed to Amgen . The repayment was effected on May 15, 2015 by Amgen withholding certain royalties that were due to the Company from SENSIPAR and MIMPARA sales in the first quarter of 2015. As at September 30, 2015 $ 1 0 . 7 million has been included within Short- term borrowings, and $ 7 0 . 7 million has been included within Long-term borrowings in respect of the remaining obligations to DRI . Short - term uncommitted lines of credit (“Credit lines”) Shire has access to various Credit lines from a number of banks which provide flexibility to short - term cash management procedures. These Credit lines can be withdrawn by the banks at any time. The Credit lines are not relied upon for core liquidity. As at September 30, 2015 these Credit lines were not utilized .

Other Non-current Liabilities

Other Non-current Liabilities	9 Months Ended
	Sep. 30, 2015
Other Liabilities, Noncurrent [Abstract]
Other non-current Liabilities Disclosure	14 . Other non-current liabilities September 30, December 31, 2015 2014 $’M $’M ____________ ____________ Income taxes payable 190.4 199.2 Contingent consideration payable 408.9 435.4 Other non-current liabilities 140.5 102.1 ____________ ____________ 739.8 736.7 ____________ ____________

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure	15 . Commitments and contingencies (a) Leases Future minimum lease payments under operating leases at September 30, 2015 are presented below: Operating leases $’M _____________ 2015 1 13.5 2016 1 44.7 2017 1 31.6 2018 1 25.3 2019 1 20.9 2020 20.0 Thereafter 1 125.8 111 _____________ 281.8 _____________ The Company leases land, facilities, motor vehicles and certain equipment under operating leases expiring through 20 32 . Lease and rental expense amounted to $ 30.6 million and $ 29.3 million for the nine months to September 30, 2015 and 2014 respectively , which is predominately included in SG&A expenses in the Company's c onso lidated i ncome statement . (b) Letters of credit and guarantees At September 30 , 2015 the Company had irrevocable standby letters of credit and guarantees with various banks and insurance companies totaling $ 49 .0 m illion (being the contractual amounts) , providing security for the C ompany's performance of various obligations. These obligations are primarily in respect of the recoverability of insurance claims, lease obligations and supply comm itments. (c) Collaborative and other licensing arrangements Details of significant updates in collaborative and other licensing arrangements are included below: Out-licensing arrangements On September 1, 2015 Shire and Sangamo BioSciences , Inc. (“ Sangamo ”) agreed to revise the collaboration and license agreement originally entered into in January 2012 to expedite the development of ZFP Therapeutics for hemophilia A and B and Huntington's disease. Under the revised terms, Shire has returned to Sangamo the exclusive world-wide rights to gene targets for the development, clinical testing and commercialization of ZFP Therapeutic s for hemophilia A and B, and has retain ed rights and will continue to develop ZFP Therapeutic clinical leads for Huntington's disease and a ZFP Therapeutic for one additional gene target. E ach company will be responsible for expenses associated with its own programs and will reimburse the other for any ongoing services provided. Sangamo has granted Shire a right of first negotiation to license the hemophilia A and B programs. No milestone payments will be made on any program and each company will pay certain royalties to the other on commercial sales up to a specified maximum cap . Shire has entered into various other collaborative and out-licensing arrangements under which the Company has out-licensed certain product or intellectual property rights for consideration such as up-front payments, development milestones, sales milestones and/or royalty payments. In some of these arrangements Shire and the licensee are both actively involved in the development and commercialization of the licensed product and have exposure to risks and rewards dependent on its commercial success. Under the terms of these collaborative and out-licensing arrangements, the Company may receive development milestone payments up to an aggregate amount of $ 39 million and sales milestones up to an aggregate amount of $ 46 million. The receipt of these substantive milestones is uncertain and contingent on the achievement of certain development milestones or the achievement of a specified level of annual net sa les by the licensee . In the nine months to September 30, 2015 Shire received cash in respect of up-front and milestone payments totaling $ 1 2. 6 million (2014 : $ 1 .0 million ). In the nine months to September 30, 2015 Shire recognized milestone income of $ 1. 5 million (2014 : $ 3 . 6 million) in o ther revenues and $ 37 . 2 million (2014 : $ 39 . 8 million ) in p roduct sales for shipment of product to the relevant licensee. (d) Commitments ( i ) Clinical testing At September 30, 2015 the Company had committed to pay approximately $ 454 million (December 31, 2014 : $ 382 million) to contract vendors for administering and executing clinical trials. The timing of these payments is dependent upon actual services performed by the organizations as determined by patient enrollment levels and related activities. (ii) Contract manufacturing At September 30, 2015 the Company had committed to pay approximately $ 321 million (December 31, 2014 : $ 384 million) in respect of contract manufacturing. The Company expects to pay $ 71 million of these commitments in 201 5 . (iii) Other purchasing commitments At September 30, 2015 the Company had committed to pay approximately $ 352 million (December 31, 2014 : $ 265 million) for future purchases of goods and services, predominantly relating to active pharmaceutical ingredients sourcing. The Company expects to pay $ 331 million of these commitments in 201 5 . (iv) Investment commitments At September 30, 2015 the Company had outstanding commitments to subscribe for interests in companies and partnerships for amounts totaling $ 49 million (December 31, 2014 : $ 67 million) which may all be payable in 201 5 , depending on the timing of capital calls. The investment commitments include additional funding to certain VIE s of which Shire is not the primary beneficiary. (v) Capital commitments At September 30, 2015 the Company had committed to spend $ 21 million (December 31, 2014 : $ 3 million) on capital projects. (e) L egal and other proceedings The Company expenses legal costs as they are incurred. The Company recognizes loss contingency provisions for probable losses when management is able to reasonably estimate the loss. When the estimated loss lies within a range, the Company records a loss contingency provision based on its best estimate of the probable loss. If no particular amount within that range is a better estimate than any other amount, the minimum amount is recorded. Estimates of losses may be developed substantially before the ultimate loss is known, and are therefore refined each accounting period as additional information becomes known. In instances where the Company is unable to develop a reasonable estimate of loss, no loss contingency provision is recorded at that time. As information becomes known a loss contingency provision is recorded when a reasonable estimate can be made. The estimates are reviewed quarterly and the estimates are changed when expectations are revised. An outcome that deviates from the Company's estimate may result in an additional expense or release in a future accounting period. At September 30, 2015 , provisions for litigation losses, insurance claims and other disputes totaled $ 9.5 million (December 31, 2014 : $ 16.9 million) . The Company's principal pending legal and other proceedings are disclosed below. The outcomes of these proceedings are not always predictable and can be affected by various factors. For those legal and other proceedings for which it is considered at least reasonably possible that a loss has been incurred, the Company discloses the possible loss or range of possible loss in excess of the recorded loss contingency provision, if any, where such excess is both material and estimable. VYVANSE In May and June 2011, Shire was notified that six separate Abbreviated New Drug Applications ("ANDAs") were submitted under the Hatch-Waxman Act seeking permission to market generic versions of all approved strengths of VYVANSE. The notices were from Sandoz, Inc. ("Sandoz"); Amneal Pharmaceuticals LLC (" Amneal "); Watson Laboratories, Inc . (“Watson”) ; Roxane Laboratories, Inc. ("Roxane"); Mylan Pharmaceuticals, Inc. (“ Mylan ”) ; and Actavis Elizabeth LLC and Actavis Inc. (collectively, " Actavis "). Since filing suit against these ANDA filers, along with API suppliers Johnson Matthey Inc. and Johnson Matthey Pharmaceuticals Materials (collectively “Johnson Matthey”), Shire has been engaged in a consolidated patent infringement litigation in the US District Court for the District of New Jersey against the aforementioned parties (except Watson, who withdrew their ANDA). On June 23, 2014, the US District Court for the District of New Jersey granted Shire's summary judgment motion holding that 18 claims of the patents-in-suit were both infringed and valid. On September 24, 2015, the US Court of Appeals of the Federal Circuit (“CAFC”) affirmed that ruling against all of the ANDA filers and remanded the case to the trial court for further proceedings in which Shire expects the court to impose an injunction preventing all of the ANDA filers (Sandoz, Roxane, Amneal , Actavis and Mylan ) from launching generic versions of VYVANSE until the expiration of these patents in 2023. LIALDA In May 2010, Shire was notified that Zydus Pharmaceuticals USA, Inc. (“ Zydus ”) had submitted an ANDA under the Hatch-Waxman Act seeking permission to market a generic version of LIALDA. Within the requisite 45 day period, Shire filed a lawsuit in the US District Court for the District of Delaware against Zydus and Cadila Healthcare Limited, doing business as Zydus Cadila . A Markman hearing took place on January 29, 2015 and a Markman ruling was issued on July 28, 2015 . A trial is scheduled to take place starting on March 28, 2016 . In February 2012, Shire was notified that Osmotica Pharmaceutical Corporation (" Osmotica ") had submitted an ANDA under the Hatch-Waxman Act seeking permission to market a generic version of LIALDA. Within the requisite 45 day period, Shire filed a lawsuit in the US District Court for the Northern District of Georgia against Osmotica . A Markman hearing took place on August 22, 2013 and a Markman ruling was issued on September 25, 2014. The Court issued an Order on February 27, 2015 in which all dates in the scheduling order have been stayed. In March 2012, Shire was notified that Watson Laboratories Inc.-Florida had submitted an ANDA under the Hatch-Waxman Act seeking permission to market a generic version of LIALDA. Within the requisite 45 day period, Shire filed a lawsuit in the US District Court for the Southern District of Florida against Watson Laboratories Inc.-Florida and Watson Pharmaceuticals, Inc. Watson Pharma, Inc. and Watson Laboratories, Inc. were subsequently added as defendants. A trial took place in April, 2013 and on May 9, 2013 the trial court issued a decision finding that the proposed generic product infringes the patent-in-suit and that the patent is not invalid. Watson appealed the trial court's ruling to the CAFC and a hearing took place on December 2, 2013. The ruling of the CAFC was issued on March 28, 2014 overruling the trial court on the interpretation of two claim terms and remanding the case for further proceedings. Shire petitioned the Supreme Court for a writ of certiori , which was granted on January 26, 2015. The Supreme Court also vacated the CAFC decision and remanded the case to the CAFC for further consideration in light of the Supreme Court's recent decision in Teva v Sandoz. On June 3, 2015, the CAFC reaffirmed its previous decision to reverse the district court's claims construction. The case has been remanded to the district court and a trial is scheduled to take place starting on January 25, 2016. In April 2012, Shire was notified that Mylan had submitted an ANDA under the Hatch-Waxman Act seeking permission to market a generic version of LIALDA. Within the requisite 45 day period, Shire filed a lawsuit in the US District Court for the Middle District of Florida against Mylan . A Markman hearing took place on December 22, 2014. A Markman ruling was issued on March 23, 2015. The previously scheduled trial date has been vacated and the case has been stayed until May 31, 2016. In March 2015, Shire was notified that Amneal had submitted an ANDA under the Hatch-Waxman Act seeking permission to market a generic version of LIALDA. Within the requisite 45 day period, Shire filed a lawsuit in the US District Court for the District of New Jersey against Amneal , Amneal Pharmaceuticals of New York, LLC and Amneal Pharmaceuticals Co. India Pvt. Ltd. No trial date has been set. In September 2015, Shire was notified that Lupin Ltd. had submitted an ANDA under the Hatch-Waxman Act seeking permission to market a generic version of LIALDA . Shire is reviewing the notice letter . On October 7, 2015 the Patent Trial and Appeals Board (“PTAB”) of the United States Patent Office instituted an inter parties review (“IPR”) of US Patent 6,773,720 which is the patent-in-suit in the litigations referred to above. The IPR process is designed to re-assess the patentability of the claims of the patent. A decision from the PTAB is expected in October 2016. Investigation related to DERMAGRAFT The Department of Justice, including the US Attorney's Office for the Middle District of Florida, Tampa Division and the US Attorney's Office for Washington, DC, is conducting civil and criminal investigations into the sales and marketing practices of Advanced BioHealing Inc. (“ABH”) relating to DERMAGRAFT. Following the disposal of the DERMAGRAFT business in January 2014, Shire has retained certain legacy liabilities including any liability that may arise from this investigation. Shire is cooperating fully with these investigations. Shire is not in a position at this time to predict the scope, duration or outcome of these investigations. Civil Investigative Demand relating to VANCOCIN On April 6, 2012, ViroPharma received a notification that the United States Federal Trade Commission (“FTC”) is conducting an investigation into whether ViroPharma had engaged in unfair methods of competition with respect to VANCOCIN. On August 3, 2012, and September 8, 2014, ViroPharma and Shire respectively received Civil Investigative Demands from the FTC requesting additional information related to this matter. Shire intends to continue to cooperate fully with the FTC investigation. At this time, Shire is unable to predict the outcome or duration of this investigation. Lawsuit related to supply of ELAPRASE to certain patients in Brazil On September 24, 2014 Shire's Brazilian affiliate, Shire Farmaceutica Brasil Ltda , was served with a lawsuit brought by the State of Sao Paulo and in which the Brazilian Public Attorney's office has intervened alleging that Shire is obligated to provide certain medical care including ELAPRASE for an indefinite period at no cost to patients who participated in ELAPRASE clinical trials in Brazil, and seeking recoupment to the Brazilian government for amounts paid for these patients to date, and moral damages associated with these claims. Shire intends to defend itself against these allegations but is not able to predict the outcome or duration of this case.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	9 Months Ended
	Sep. 30, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Income (Loss)	16 . Accumulated O ther Comprehensive loss The changes in accumulated other comprehensive loss , net of their related tax effects, in the nine months to September 30, 2015 and 2014 are included below: As at September 30, 2015 Foreign currency translation adjustment Unrealized holding gain/(loss) on available-for-sale securities Accumulated other comprehensive loss $M $M $M As at January 1, 2015 (25.7) (5.8) (31.5) Current period change: Net current period other comprehensive (loss)/income (124.9) 1.3 (123.6) As at September 30, 2015 (150.6) (4.5) (155.1) As at September 30, 2014 Foreign currency translation adjustment Unrealized holding gain/(loss) on available-for-sale securities Accumulated other comprehensive income $M $M $M As at January 1, 2014 110.4 (0.2) 110.2 Current period change: Other comprehensive (loss)/income before reclassification (75.9) 5.6 (70.3) Gain transferred to the income statement (within Other income, net) on disposal of available-for-sale securities - (9.1) (9.1) Net current period other comprehensive loss (75.9) (3.5) (79.4) As at September 30, 2014 34.5 (3.7) 30.8

Financial Instruments

Financial Instruments	9 Months Ended
	Sep. 30, 2015
Derivative Instrument Detail [Abstract]
Financial Instruments Disclosure	17 . Financial instruments Treasury policies and organization The Company's principal treasury operations are coordinated by its corporate treasury function. All treasury operations are conducted within a framework of policies and procedures approved annually by the Board. As a matter of policy, the Company does not undertake speculative transactions that would increase its currency or interest rate exposure . Interest rate risk The Company is principally exposed to interest rate risk on borrowings under the 2015 Facility Agreement, the RCF and the Credit lines, on which interest is set at floating rates, to the extent any of these facilities, are utilized. At September 30, 2015 the Company had fully utilized the 2015 Facility Agreement and utilized $1,245 million of the RCF. The Credit lines were not utilized. Shire's exposure under the 2015 Facility Agreement, the RCF and the Credit lines is to US dollar interest rates . The Company has evaluated the interest rate risk on the Credit lines, the RCF and the 2015 Facility Agreement and considers the risks associated with floating interest rates on borrowings under its facilities as appropriate. A hypothetical one percentage point increase or decrease in the interest rates applicable to drawi ngs under the Credit lines, the 2015 Facility Agreement and RCF at September 30, 2015 would increase interest expense by approximately $ 20 million pe r annum or would decrease the interest expense by approximately $ 4 million per annum. The Company is also exposed to interest rate risk on its restricted cash, cash and cash equivalents and on foreign exchange contracts on which interest is set at floating rates. This exposure is primarily limited to US dollar, Pounds sterling and Euro interest rates. As the Company maintains all of its cash, liquid investments and foreign exchange contracts on a short term basis for liquidity purposes, this risk is not actively managed. In the nine months to September 30, 2015 the average interest rate received on cash and liquid investments was less than 1% per annum. These cash and liquid investments were primarily invested in US dollar term deposits with banks and money market and liquidity funds. No derivative instruments were entered into during the nine months to September 30, 2015 to manage interest rate exposure. The Company continues to review its interest rate risk and the policies in place to manage the risk . Credit risk Financial instruments that potentially expose Shire to concentrations of credit risk consist primarily of short-term cash investments, derivative contracts and trade accounts receivable (from product sales and from third parties from which the Company receives royalties). Cash is invested in short-term money market instruments, including money market and liquidity funds and bank term deposits. The money market and liquidity funds in which Shire invests are all triple A rated by both Standard and Poor's and by Moody's credit rating agencies. The Company is exposed to the credit risk of the counterparties with which it enters into bank term deposit arrangements and derivative instruments. The Company limits this exposure through a system of internal credit limits which vary according to ratings assigned to the counterparties by the major rating agencies. The internal credit limits are approved by the Board and exposure against these limits is monitored by the corporate treasury function. The counterparties to these derivatives contracts are major international financial institutions. The Company's revenues from product sales in the US are mainly governed by agreements with major pharmaceutical wholesalers and relationships with other pharmaceutical distributors and retail pharmacy chains. F or the year to December 31, 201 4 there were three customers in the US that accounted for 47% of the Company's product sales. However, such customers typically have significant cash resources and as such the risk from concentration of credit is considered acceptable. The Company has taken positive steps to manage any credit risk associated with these transactions and operates clearly defined credit evaluation procedures . However, an inability of one or more of these wholesalers to honor their debts to the Company could have an adverse effect on the Company's financial condition and results of operations . A substantial portion of the Company's accounts receivable in countries outside of the United States is derived from product sales to government-owned or government-supported healthcare providers. The Company's recovery of these accounts receivable is therefore dependent upon the financial stability and creditworthiness of the relevant governments. In recent years global and national economic conditions have negatively affected the growth, creditworthiness and general economic condition of certain markets in which the Company operates. As a result, in some countries outside of the US , specifically, Argentina , Greece, Italy, Portugal and Spain (collectively the “Relevant Countries”) the Company is experiencing delays in the remittance of receivables due from government-owned or government-supported healthcare providers. The Company continue d to receive remittances in relation to government-owned or government-supported healthcare providers in the Relevant Countries in the nine months to September 30, 2015 , including receipts of $ 80.6 million and $ 65.7 million in respect of Spanish and Italian receivables, respectively . The Company's exposure to Greece, both in terms of gross accounts receivable and annual revenues, is not material. To date the Company has not incurred material losses on accounts receivable in the Relevant Countries, and continues to consider that such accounts receivable are recoverable. The Company will continue to evaluate all its accounts receivable for potential collection risks and has made provision for amounts where collection is considered to be doubtful. If the financial condition of the Relevant Countries or other Eurozone countries suffer significant deterioration, such that their ability to make payments becomes uncertain, or if one or more Eurozone member countries withdraws from the Euro, additional allowances for doubtful accounts may be required, and losses may be incurred, in future periods. Any such loss could have an adverse effect on the Company's financial condition and results of operations. Foreign exchange risk The Company trades in numerous countries and as a consequence has transactional and translational foreign exchange exposures. Transactional exposure arises where transactions occur in currencies different to the functional currency of the relevant subsidiary. The main trading currencies of the Company are the US dollar, Pounds Sterling, Swiss Franc , Canadian dollar and the Euro. It is the Company's policy that these exposures are minimized to the extent practicable by denominating transactions in the subsidiary's functional currency. Where significant exposures remain, the Company uses foreign exchange contracts (being spot, forward and swap contracts) to manage the exposure for balance sheet assets and liabilities that are denominated in currencies different to the functional currency of the relevant subsidiary. These assets and liabilities relate predominantly to inter - company financing. The foreign exchange contracts have not been designated as hedging instruments. Cash flows from derivative instruments are presented within net cash provided by operating activities in the consolidated cash flow statement, unless the derivative instruments are economically hedging specific investing or financing activities. Translational foreign exchange exposure arises on the translation into US dollars of the financial statements of non-US dollar functional subsidiaries . At September 30, 2015 the Company h ad 33 swap and forward foreign exchange contracts outstanding to manage currency risk. The swap and forward contracts mature within 90 days. The Company did not have credit risk related contingent features or collateral linked to the derivatives. The Company has master netting agreements with a number of counterparties to the se foreign exchange contracts and on the occurrence of specified events, the Company has the ability to terminate contracts and settle them with a net payment by one party to the other. T he Company has elected to present derivative assets and derivative liabilities on a gross basis in the consolidated balance sheet. As a t September 30, 2015 the po tential effect of rights of set- off associated with the foreign exchange contracts would be an offset to both assets and liabilities of $ 1.4 million, resulting in net derivative assets and derivative liabilities of $ 0.4 million and $ 7.7 million, respectively . Further details are included below : Fair value Fair value September 30, December 31, 2015 2014 $’M $’M _____________ _____________ Assets Prepaid expenses and other current assets 1.8 12.6 Liabilities Other current liabilities 9.1 7.8 _____________ _____________ Net gains (both realized and unrealized) arising on foreign exchange contracts have been classified in the consolidated statements of income as follows: Location of net gains recognized in income Amount of net gains recognized in income __________________________________ ____________ In the nine months to September 30, September 30, 2015 2014 $’M $’M _____________ _____________ Foreign exchange contracts Other income, net 12.0 15.9 _____________ _____________ These net foreign exchange gains are offset within Other income, net by net foreign exchange ( losses )/gains arising on the ba lance sheet items that these contracts were put in place to manag e .

Fair Value Measurement

Fair Value Measurement	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures	18. Fair value measurement Assets and l iabilities that are m easured at f air v alue on a r ecurring b asis As at September 30, 2015 and December 31, 201 4 t he following financial assets and liabilities are measured at fair value on a recurring basis using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3). Carrying value and Fair value Total Level 1 Level 2 Level 3 At September 30, 2015 $'M $'M $'M $'M ____________ ___________ ___________ ___________ Financial assets: Available-for-sale securities (1) 14.4 14.4 - - Contingent consideration receivable (2) 14.9 - - 14.9 Foreign exchange contracts 1.8 - 1.8 - Financial liabilities: Foreign exchange contracts 9.1 - 9.1 - Contingent consideration payable (3) 520.6 - - 520.6 ____________ ___________ ___________ ___________ Total Level 1 Level 2 Level 3 At December 31, 2014 $'M $'M $'M $'M ____________ ___________ ___________ ___________ Financial assets: Available-for-sale securities (1) 13.1 13.1 - - Contingent consideration receivable (2) 15.9 - - 15.9 Foreign exchange contracts 12.6 - 12.6 - Financial liabilities: Foreign exchange contracts 7.8 - 7.8 - Contingent consideration payable (3) 1 629.9 - - 629.9 ____________ ___________ ___________ ___________ Available-for-sale securities are included within Investments in the consolidated balance sheet. (2) Contingent consideration receivable is included within Prepaid expenses and other current assets and Other non-current assets in the consolidated balance sheet . (3) Contingent consideration payable is included within Other current liabilities and O ther non- current liabilities in the consolidated balance sheet. Certain estimates and judgments were required to develop the fair value amounts. The fair value amounts shown above are not necessarily indicative of the amounts that the Company would realize upon disposition, nor do they indicate the Company's intent or ability to dispose of the financial instrument. The following methods and assumptions were used to estimate the fair value of each material class of financial instrument: Available-for-sale securities – the fair values of available-for-sale securities are estimated based on quoted market prices for those investments. Contingent consideration receivable – the fair value of the contingent consideration receivable has been estimated using the income approach (using a probability weighted discounted cash flow method). Foreign exchange contracts – the fair values of the swap and forward foreign exchange contracts have been determined using an income approach based on current market expectations about the future cash flows. Contingent consideration payable – the fair value of the contingent consideration payable has been estimated using the income approach (using a probability weighted discounted cash flow method). Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3) The change in the fair value of the Company's contingent consideration receivable and payables, which are measured at fair value on a recurring basis using significant unobservable inputs (Level 3) , are as follows: Contingent consideration receivable 2015 2014 $'M $'M ____________ ____________ Balance at January 1, 15.9 36.1 Initial recognition of contingent consideration receivable - 33.6 Loss recognized in the income statement (within discontinued operations) due to change in fair value during the period - (33.6) Gain/(loss) recognized in the income statement (within Gain on sale of product rights) due to change in fair value during the period 9.8 (4.1) Reclassification of amounts to Other receivables within Other current assets (12.1) (14.9) Amounts recorded to other comprehensive income (within foreign currency translation adjustments) 1.3 2.0 Balance at September 30, 14.9 19.1 Contingent consideration payable 2015 2014 $'M $'M ____________ ____________ Balance at January 1, 629.9 405.9 Initial recognition of contingent consideration payable 92.8 226.7 Change in fair value during the period with the corresponding adjustment recognized (within Integration and acquisition costs) in the income statement (196.5) 26.3 Reclassification of amounts to Other current liabilities (8.5) (12.4) Change in fair value during the period with corresponding adjustment to the associated intangible asset 0.2 1.8 Amounts recorded to other comprehensive income (within foreign currency translation adjustments) 2.7 (6.3) Balance at September 30, 520.6 642.0 Of the $ 520.6 million of contingent consideration payable as at September 3 0 , 2015 , $ 111.7 million is recorded within other current liabilities and $ 408.9 million is recorded within other non-current liabilities in the Company's balance sheet . Quantitative Information about Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3) Quantitative information about the Company's recurring Level 3 fair value measurements is included below: Financial assets: Fair Value at the Measurement Date At September 30, 2015 Fair value Valuation Technique Significant unobservable Inputs Range $'M ____________ ___________ ___________ ___________ Contingent consideration receivable ("CCR") 14.9 Income approach (probability weighted discounted cash flow) • Probability weightings applied to different sales scenarios • Future forecast consideration receivable based on contractual terms with purchaser • Assumed market participant discount rate • 10 to 70% • $26 million to $31 million • 8.7% ____________ ____________ ____________ ____________ Financial liabilities: Fair Value at the Measurement Date At September 30, 2015 Fair value Valuation Technique Significant unobservable Inputs Range $'M ____________ ___________ ___________ ___________ Contingent consideration payable 520.6 Income approach (probability weighted discounted cash flow) • Cumulative probability of milestones being achieved • Assumed market participant discount rate • Periods in which milestones are expected to be achieved • Forecast quarterly royalties payable on net sales of relevant products • 4 to 85% • 1.2 to 12.4% • 2015 to 2029 • $0.2 to $6.6 million ____________ ____________ ____________ ____________ The Company re-measures the CCR (relating to contingent consideration due to the Company following divestment of certain of the Company's products) at fair value at each balance sheet date , with the fair value measurement based on forecast cash flow s, over a number of scenarios which vary depending on the expected performance outcome of the product s following divestment. The forecast cash flows under each of these differing outcomes have been included in probability weighted estimates used by the Company in determining the fair value of the CCR. Contingent consideration payable represents future milestones the Company may be required to pay in conjunction with various business combinations and future royalt ies payable as a result of certain business combinations and license s . The amount ultimately payable by Shire in relation to business combinations is dependent upon the achievement of specified future milestones, such as the achievement of certain future development, regulatory and sales milestones. The Company assesses the probability, and estimated timing, of these milestones being achieved and re-measures the related contingent consideration to fair value each balance sheet date. The amount of contingent consideration which may ultimately be payable by Shire in relation to future royalties is dependent upon future net sales of the relevant products over the life of the royalty term . The Company assesses the present value of forecast future net sales of the relevant products and re-measures the related contingent consideration to fair value each balance sheet date. The fair value of the Company's contingent consideration receivable and payable could significantly increase or decrease due to changes in certain assumptions which underpin the fair value measurements. Each set of assumptions and milestones is specific to the individual contingent consideration receivable or payable. The assumptions include, among other things , the probability and expected timing of certain milestones being achieved, the forecast future net sales of the relevant products and related future royalties payable, the probability weightings applied to different sales scenarios of the Company's divested products and forecast future royalties receivable under scenarios developed by the Company, and the discount rates used to determine the present value of contingent future cash flows. The Company regularly reviews these assumptions, and makes adjustments to the fair value measurements as required by facts and circumstances . Assets Measured at Fair Value on a Non-Recurring Basis using Significant Unobservable Inputs (Level 3) In the nine months to September 3 0 , 201 5 the Company reviewed its SHP625 and SHP608 IPR&D intangible assets for impairment and recognized an impairment charge of $ 5 23.3 million, recorded within R&D in the consolidated income statement, to write-down these IPR&D assets to their fair value. The fair value of these IPR&D assets was determined using the income approach, which used significant unobservable (Level 3) inputs. These unobservable inputs included, among other things, the probabilities of these IPR&D assets receiving regulatory approval, the timeframe for such approval, risk-adjusted forecast future cash flows to be generated by these IPR&D assets and the determination of an appropriate discount rate to be applied in calculating the present value of forecast future cash flows. The fair value of these IPR&D assets, determined at the time of the impairment review, was $ 1 2 0. 4 million . Fair Value at the Measurement Date At September 30, 2015 Fair value Valuation Technique Significant unobservable Inputs Range $'M ____________ ___________ ___________ ___________ IPR&D intangible assets (SHP625 and SHP608) $120.4 Income approach (discounted cash flow) • Probability of regulatory approval being obtained • Expected commercial launch date • Assumed market participant discount rate • 5 to 33% • 2018 to 2021 • 9.7 to 10.7% ____________ ____________ ____________ ____________ The carrying amounts of other financial assets and liabilities materially approximate to their fair value either because of the short-term maturity of these amounts or because there have been no significant changes since the asset or liability was last re-measured to fair value on a non-recurring basis .

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Earnings Per Share Disclosure	19 . Earnings per share The following table reconciles net income and the weighted average ordinary shares outstanding for basic and diluted earnings per share for the periods presented: 3 months to 3 months to 9 months to 9 months to September 30, September 30, September 30, September 30, 2015 2014 2015 2014 $’M $’M $’M $’M _________________ _________________ _________________ _________________ Income from continuing operations, net of taxes 477.1 515.8 1,054.1 1,297.2 Loss from discontinued operations 1 (24.3) (36.1) (31.3) (64.0) _________________ _________________ _________________ _________________ Numerator for basic and diluted earnings per share 452.8 479.7 1,022.8 1,233.2 _________________ _________________ _________________ _________________ Weighted average number of shares: Millions Millions Millions Millions _________________ _________________ _________________ _________________ Basic 1 590.9 587.6 590.2 586.1 Effect of dilutive shares: Share-based awards to employees 2 2.5 5.0 3.0 6.0 _________________ _________________ _________________ _________________ Diluted 593.4 592.6 593.2 592.1 _________________ _________________ _________________ _________________ 1 . Excludes shares purchased by the EBT and presented by Shire as treasury stock . 2 . Calculated using the treasury stock method . The share equivalents not included in the calculation of the diluted weighted average number of shares are shown below: 3 months to 3 months to 9 months to 9 months to September 30, September 30, September 30, September 30, 2015 2014 2015 2014 No. of shares No. of shares No. of shares No. of shares Millions Millions Millions Millions _________________ _________________ _________________ _________________ Share-based awards to employees 1 3.9 0.3 3.3 0.3 _________________ _________________ _________________ _________________ Certain stock options have been excluded from the calculation of diluted EPS because (a) their exercise prices exceeded Shire plc's average share price during the calculation period or (b) the required performance conditions were not satisfied as at the balance sheet date.

Segmental Reporting

Segmental Reporting	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Segment Reporting Disclosure	20. Segmental reporting Shire comprises a single operating and reportable segment engaged in the research , development, licensing, manufacturing, marketing, distribution and sale of innovative specialist medicines to meet significant unmet patient needs. This segment is supported by several key functions: a Pipeline group, consisting of R&D and Corporate Development, which prioritizes its activities towards late-stage development programs across a variety of therapeutic areas, while focusing its pre-clinical development activities primarily in Rare Diseases; a Technical Operations group responsible for the Company's global supply chain; and an In-line marketed products group which focuses on commercialized products. The In-Line marketed products group has commercial units that focus exclusively on the commercial execution of its marketed products including in the areas of Rare Diseases, Neuroscience, and Gastrointestinal (“ GI ”) and Internal Medicine, and to support the development of our pipeline candidates, in Ophthalmics. This ensures that the Company provides innovative treatments, and services the needs of its customers and patients, as efficiently as possible. The business is also supported by a simplified, centralized corporate function group. None of these functional groups meets all of the criteria to be an operating segment . Th is single operating and reportable segment is consistent with the financial information regularly reviewed by the Executive Committee (which is Shire 's chief operating decision maker) for the purposes of evaluating performance, allocating resources, and planning and forecasting future periods. In the periods set out below, revenues by major product were as follows : 9 months to September 30, September 30, 2015 2014 $’M $’M ___________ ___________ VYVANSE 1,268.9 1,065.6 CINRYZE 474.4 360.6 LIALDA/MEZAVANT 483.0 449.1 ELAPRASE 405.5 449.5 FIRAZYR 319.8 262.3 REPLAGAL 325.5 380.7 PENTASA 232.7 213.8 VPRIV 256.2 273.0 ADDERALL XR 259.7 280.2 FOSRENOL 132.9 136.2 GATTEX/REVESTIVE 95.2 - XAGRID 75.0 82.1 INTUNIV 45.0 279.0 NATPARA 12.8 - Other product sales 89.6 97.6 ____________ ____________ Total product sales 4,476.2 4,329.7 ____________ ____________

Taxation

Taxation	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure	21 . Taxation The effective rate of tax in the nine months to September 30, 2015 was -1% (2014: -5%). The effective rate of tax in the nine months to September 30, 2015 on income from continuing operations is negative primarily due to the release of certain valuation allowances and the impact of the finalization of various tax returns in the period. The effective rate of tax in the nine months to September 30, 2014 on income from continuing operations was negative primarily due to the recognition of a net tax credit in relation to the settlement of tax positions with the Canadian revenue authorities.

Related Parties

Related Parties	9 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Disclosure	22 . Related parties Shire considers that ArmaGen , Inc. (“ ArmaGen ”) is a related party by virtue of a combination of Shire's equity stake in ArmaGen and the worldwide licensing and collaboration agreement between the two parties to develop and commercialize AGT-182. In the nine months to September 30, 2015 Shire paid $ 2 . 5 million in cash to ArmaGen in exchange for an additional equity stake in ArmaGen , following which Shire holds approximately 21 % of ArmaGen's issued equity. In addition, Shire recorded R&D costs ari sing from the licensing and collaboration arrangement of $ 7.2 million in the nine months to September 30, of 2015, of which $ 0.7 million was accrued and unpaid as at September 30, 2015 .

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Basis of preparation	(a) Basis of preparation These interim financial statements of Shire plc and its subsidiaries (collectively “Shire” or the “Company”) and other financial information included in this Form 10-Q, are unaudited. They have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and US Securities and Exchange Commission (“SEC”) regulations for interim reporting. The balance sheet as at December 31, 201 4 was derived from audited financial statements but does not include all disclosures required by US GAAP. These interim financial statements should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company's Annual Report on Form 10-K for the year to December 31, 201 4 . Certain information and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period and the Company believes that the disclosures are adequate to make the information presented not misleading. Interim results are not necessarily indicative of results to be expected for the full year .
Use of estimates in consolidated financial statements	(b) Use of estimates in interim financial statements The preparation of interim financial statements, in conformity with US GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of intangible assets, sales deductions, income taxes (including provisions for uncertain tax positions and the rea lization of deferred tax assets ), provisions for litigation and legal proceedings, contingent consideration receivable from product divestments and contingent consideration payable in respect of business combinations and asset purchases . If actual results differ from the Company's estimates, or to the extent these estimates are adjusted in future periods, the Company's results of operations could either benefit from, or be adversely affected by, any such change in estimate.
New accounting pronouncements	(c ) New accounting pronouncements Adopted during the period Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity In April 2014 the Financial Accounting Standard s Board (“ FASB ”) issued guidance on the reporting of discontinued operations and disclosures of disposals of components of an entity. The amendments in this update revise the definition of discontinued operations by limiting discontinued operations reporting to disposals of components of an entity that represent strategic shifts that have (or will have) a major effect on an entity's operations and financial results. The guidance requires expanded disclosures for discontinued operations which provide users of financial statements with more information about the assets, liabilities, revenues, and expenses of discontinued operations. The guidance also requires an entity to disclose the pre-tax profit or loss of an individually significant component of an entity that does not qualify for discontinued operations reporting. Shire adopted this guidance in the period, which will be effective for discontinued operations occurring after January 1, 2015. The adoption of this guidance did not impact the Company's consolidated financial position, results of operations or cash flows . To be adopted in future periods Revenue from Contracts with Customers In May 2014 the FASB and the International Accounting Standards Board (together the “Accounting Standards Boards”) issued a new accounting standard that is intended to clarify and converge the financial reporting requirements for revenue from contracts with customers. The core principle of the standard is that an “entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services”. To achieve that core principle the Accounting Standard s Boards developed a five-step model (as presented below) and related application guidance, which will replace most existing revenue recognition guidance in US GAAP. Five-step model: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The Accounting Standards Boards also issued new qualitative and quantitative disclosure requirements as part of the new accounting standard which aims to enable financial statement users to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. In August 2015 the FASB decided to defer the effective date of the guidance by one year. Based on this deferral , public entities would need to apply the new guidance for annual reporting periods beginning after December 15, 2017, and interim periods therein. The Company is currently evaluating the impact of adopting this guidance . Amendments to the Consolidation Analysis In February 201 5 the FASB issued guidance to respond to stakeholders' concerns about the current accounting for consolidation of certain legal entities. Financial statement users asserted that in certain situations in which consolidation is ultimately required, deconsolidated financial statements are necessary to better analyze the reporting entity's economic and operational results. Previously, the FASB issued an indefinite deferral for certain entities to partially address those concerns. However, the amendments in this guidance rescind that deferral and address those concerns by making changes to the consolidation guidance. Under the amendments, all reporting entities are within the scope of Subtopic 810-10, Consolidation , including limited partnerships and similar legal entities, unless a scope exception applies. The presumption that a general partner controls a limited partnership has been eliminated. In addition, fees paid to decision makers that meet certain conditions no longer cause decision makers to consolidate a VIE in certain instances. The amendments place more emphasis in the consolidation evaluation on variable interests other than fee arrangements such as principal investment risk (for example, debt or equity interests), guarantees of the value of the assets or liabilities of the VIE, written put options on the assets of the VIE, or similar obligations, including some liquidity commitments or agreements (explicit or implicit). Additionally, the amendments reduce the extent to which related party arrangements cause an entity to be considered a primary beneficiary. The amendments are effective for public business entities for fiscal years, and for interim periods therein, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. The Company does not expect the adoption of this guidance to have a material effect on its consolidated financial position, results of operations and cash flows. Simplify ing the Presentation of Debt Issuance Costs In April 201 5 the FASB issued guidance to simplify the presentation of debt issuance costs . The guidance require s that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this u pdate. In August 2015 the FASB issued further guidance to incorporate the SEC staff's observation that , given the absence of authoritative guidance , the SEC staff would not object to an entity deferring and presenting debt issuance costs arising from line-of-credit arrangements as an asset and subsequently amortizing these costs ratably over the term of the line-of-credit arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. T he amendments in these updates are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods therein. Early adoption is permitted for financial statements that have not been previously issued. An entity should apply the new guidance on a retrospective basis, wherein the balance sheet of each individual period presented should be adjusted to reflect the period-specific effects of applying the new guidance. Upon transition, an entity is required to comply with the applicable disclosures for a change in an accounting principle. The Company does not expect the adoption of this guidance to have a material effect on its consolidated financial position, results of operations and cash flows . Customer's Accounting for Fees Paid in a Cloud Computing Arrangement In April 2015 the FASB issued guidance to simplify the customer's accounting for fees paid in a cloud computing arrangement. The amendments provide guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The amendments will be effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted for all entities. An entity can elect to adopt the guidance either a) prospectively to all arrangements entered into or materially modified after the effective date or b) retrospectively. The Company is currently evaluating the impact of adopting this guidance . Simplifying the Measurement of Inventory In July 2015 the FASB issued guidance to simplify the measurement of i nventory which currently requires an entity to measure its inventory at the lower of cost or market, whereby market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. The amendment provide s guidance that an entity should measure inventory within the scope of this u pdate at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using l ast in first out or the retail inventory method. Th is amendment will be effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2016. Early adoption is permitted for all entities. The Company is currently evaluating the impact of adopting this guidance . Simplifying the Accounting for Measurement-Period Adjustments In September 2015 the FASB issued guidance to simplify the accounting for measurement -period adjustment. The amendments in this update require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The guidance further requires that the acquirer record, in the same period's financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date and present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. The guidance will be effective for fiscal year beginning after December 15, 2015, including interim periods within those fiscal years. The guidance should be applied prospectively to adjustments to provisional amounts that occur after the effective date of this update with earlier application permitted for financial statements that have not been issued.

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2015
NPS Pharma
Business Acquisition [Line Items]
Schedule of Purchase Price Allocation	Preliminary Fair value $’M ASSETS Current assets: Cash and cash equivalents 41.6 Short-term investments 67.0 Accounts receivable 33.4 Inventories 89.4 Deferred tax assets 156.3 Other current assets 11.1 _______________ Total current assets 398.8 Non-current assets: PP&E 4.8 Goodwill 1,679.4 Other intangible assets - currently marketed products 4,640.0 - royalty rights (categorized as "Other amortized intangible assets" ) 353.0 _______________ Total assets 7,076.0 _______________ LIABILITIES Current liabilities: Accounts payable and other current liabilities 72.5 Short-term debt 27.4 Non-current liabilities: Long-term debt, less current portion 78.9 Deferred tax liabilities 1,673.1 Other non-current liabilities 4.5 _______________ Total liabilities 1,856.4 _______________ Fair value of identifiable assets acquired and liabilities assumed 5,219.6 Consideration _______________ Cash consideration paid 5,219.6 _______________
Business Acquisition, Pro Forma Information	9 months to 9 months to September 30, September 30, 2015 2014 $’M $’M _______________ _______________ Revenues 4,730.9 4,603.4 Net income from continuing operations 1,005.6 1,028.8 _______________ _______________ Per share amounts: Net income from continuing operations per share - basic 170.4c 175.5c Net income from continuing operations per share - diluted 169.5c 173.8c _______________ _______________
Viropharma
Business Acquisition [Line Items]
Schedule of Purchase Price Allocation	Acquisition date fair value $’M Identifiable assets acquired and liabilities assumed ASSETS Current assets: Cash and cash equivalents 232.6 Short-term investments 57.8 Accounts receivable 52.2 Inventories 203.6 Deferred tax assets 100.7 Purchased call option 346.7 Other current assets 50.9 _______________ Total current assets 1,044.5 Non-current assets: PP&E 24.7 Goodwill 1,655.5 Other intangible assets - Currently marketed products 2,320.0 - In-Process Research and Development (“IPR&D”) 315.0 Other non-current assets 10.4 _______________ Total assets 5,370.1 _______________ LIABILITIES Current liabilities: Accounts payable and other current liabilities 122.7 Convertible bond 551.4 Non-current liabilities: Deferred tax liabilities 603.5 Other non-current liabilities 95.5 _______________ Total liabilities 1,373.1 _______________ Fair value of identifiable assets acquired and liabilities assumed 3,997.0 _______________ Consideration Cash consideration paid 3,997.0 _______________

Reorganization costs (Table)

Reorganization costs (Table)	9 Months Ended
	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
Schedule of Reorganization costs	Opening liability Amount Closing liability at at January 1, charged to re- September 30, 2015 organization Paid/Utilized 2015 $'M $'M $'M $'M ___________ ____________ ___________ ___________ Involuntary termination benefits 38.0 38.5 (53.7) 22.8 Other reorganization costs - 21.1 (10.4) 10.7 ___________ ___________ ___________ ___________ 38.0 59.6 (64.1) 33.5 ___________ ___________ ___________ ___________

Accounts Receivable, Net (Table

Accounts Receivable, Net (Tables)	9 Months Ended
	Sep. 30, 2015
Receivables [Abstract]
Provision for discounts and doubtful accounts	2015 2014 $’M $’M _____________ _____________ As at January 1, 48.5 47.9 Provision charged to operations 293.8 228.1 Provision utilization (286.6) (229.8) _____________ _____________ As at September 30, 55.7 46.2 _____________ _____________

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory	September 30, December 31, 2015 2014 $’M $’M ____________ ____________ Finished goods 161.0 136.0 Work-in-progress 334.9 305.3 Raw materials 113.0 103.5 ____________ ____________ 608.9 544.8 ____________ ____________

Prepaid Expenses and Other Cu38

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2015
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expense and Other Assets, Current	September 30, December 31, 2015 2014 $’M $’M ______________ ____________ Prepaid expenses 50.6 36.9 Income tax receivable 96.5 121.5 Value added taxes receivable 18.8 13.8 Other current assets 49.1 49.3 ______________ ______________ 215.0 221.5 ______________ ______________

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Acquired Goodwill	September 30, December 31, 2015 2014 $’M $’M ____________ ____________ Goodwill arising on businesses acquired 4,289.6 2,474.9 ____________ ____________
Schedule of Goodwill	2015 2014 $’M $’M ____________ ____________ As at January 1, 2,474.9 624.6 Acquisitions 1,837.0 1,773.8 Foreign currency translation (22.3) (24.7) ____________ ____________ As at September 30, 4,289.6 2,373.7 ____________ ____________

Other Intangible Assets, Net (T

Other Intangible Assets, Net (Tables)	9 Months Ended
	Sep. 30, 2015
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Schedule of Other Intangible Assets	September 30, December 31, 2015 2014 $’M $’M ________________ ________________ Amortized intangible assets Intellectual property rights acquired for currently marketed products 9,388.5 4,816.9 Other intangible assets 1 375.0 30.0 ________________ ________________ 9,763.5 4,846.9 Unamortized intangible assets Intellectual property rights acquired for IPR&D 1,482.4 1,550.0 ________________ ________________ 11,245.9 6,396.9 Less: Accumulated amortization 2 (1,795.3) (1,462.5) ________________ ________________ 9,450.6 4,934.4 ________________ ________________
Intangible Assets (Excluding Goodwill) Roll Forward	Other intangible assets 2015 2014 $’M $’M ________________ ________________ As at January 1, 4,934.4 2,312.6 Acquisitions 5,473.7 3,332.8 Divestment of non-core products - (17.3) Amortization charged (352.3) (181.9) Impairment charges (523.3) (188.0) Foreign currency translation (81.9) (30.8) ________________ ________________ As at September 30, 9,450.6 5,227.4 ________________ ________________

Accounts Payable and Accrued 41

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2015
Accounts Payable and Accrued Liabilities, Current [Abstract]
Schedule of Accounts Payable and Accrued Expenses	September 30, December 31, 2015 2014 $’M $’M ________________ ________________ Trade accounts payable and accrued purchases 313.2 247.7 Accrued rebates – Medicaid 636.4 563.9 Accrued rebates – Managed care 336.5 318.2 Sales return reserve 141.8 131.7 Accrued bonuses 133.7 150.7 Accrued employee compensation and benefits payable 118.9 109.1 R&D accruals 71.5 88.3 Other accrued expenses 249.8 299.8 ________________ ________________ 2,001.8 1,909.4 ________________ ________________

Other Current Liabilities (Tabl

Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2015
Other Liabilities, Current [Abstract]
Schedule of Other Current Liabilities	September 30, December 31, 2015 2014 $’M $’M _____________ _____________ Income taxes payable 76.0 16.2 Value added taxes 21.6 16.6 Contingent consideration payable 111.7 194.5 Other current liabilities 47.7 35.2 _____________ _____________ 257.0 262.5 _____________ _____________

Borrowings (Tables)

Borrowings (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Schedule of Borrowings	September 30, December 31, 2015 2014 $’M $’M _____________ _____________ Short term borrowings: Borrowings under the 2015 Facility Agreement 750.0 - Borrowings under the 2013 Facilities Agreement - 850.0 Borrowings under the RCF 1,245.0 - Secured non-recourse debts 10.7 - _____________ _____________ 2,005.7 850.0 Long term borrowings: Secured non-recourse debts 70.7 - _____________ _____________ 2,076.4 850.0 _____________ _____________

Other Non-current Liabilities (

Other Non-current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2015
Other Liabilities, Noncurrent [Abstract]
Schedule of Other Noncurrent Liabilities	September 30, December 31, 2015 2014 $’M $’M ____________ ____________ Income taxes payable 190.4 199.2 Contingent consideration payable 408.9 435.4 Other non-current liabilities 140.5 102.1 ____________ ____________ 739.8 736.7 ____________ ____________

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Lease Payments under Operating Leases	Operating leases $’M _____________ 2015 1 13.5 2016 1 44.7 2017 1 31.6 2018 1 25.3 2019 1 20.9 2020 20.0 Thereafter 1 125.8 111 _____________ 281.8 _____________

Accumulated Other Comprehensi46

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Changes in Accumulated Other Comprehensive Income, Net of Tax	As at September 30, 2015 Foreign currency translation adjustment Unrealized holding gain/(loss) on available-for-sale securities Accumulated other comprehensive loss $M $M $M As at January 1, 2015 (25.7) (5.8) (31.5) Current period change: Net current period other comprehensive (loss)/income (124.9) 1.3 (123.6) As at September 30, 2015 (150.6) (4.5) (155.1) As at September 30, 2014 Foreign currency translation adjustment Unrealized holding gain/(loss) on available-for-sale securities Accumulated other comprehensive income $M $M $M As at January 1, 2014 110.4 (0.2) 110.2 Current period change: Other comprehensive (loss)/income before reclassification (75.9) 5.6 (70.3) Gain transferred to the income statement (within Other income, net) on disposal of available-for-sale securities - (9.1) (9.1) Net current period other comprehensive loss (75.9) (3.5) (79.4) As at September 30, 2014 34.5 (3.7) 30.8

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2015
Derivative Instrument Detail [Abstract]
Schedule of Foreign Exchange Contracts, Statement of Financial Position	Fair value Fair value September 30, December 31, 2015 2014 $’M $’M _____________ _____________ Assets Prepaid expenses and other current assets 1.8 12.6 Liabilities Other current liabilities 9.1 7.8 _____________ _____________
Schedule of Foreign Exchange Contracts, Gain (Loss) in Other Income (Expense)	Location of net gains recognized in income Amount of net gains recognized in income __________________________________ ____________ In the nine months to September 30, September 30, 2015 2014 $’M $’M _____________ _____________ Foreign exchange contracts Other income, net 12.0 15.9 _____________ _____________

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Carrying value and Fair value Total Level 1 Level 2 Level 3 At September 30, 2015 $'M $'M $'M $'M ____________ ___________ ___________ ___________ Financial assets: Available-for-sale securities (1) 14.4 14.4 - - Contingent consideration receivable (2) 14.9 - - 14.9 Foreign exchange contracts 1.8 - 1.8 - Financial liabilities: Foreign exchange contracts 9.1 - 9.1 - Contingent consideration payable (3) 520.6 - - 520.6 ____________ ___________ ___________ ___________ Total Level 1 Level 2 Level 3 At December 31, 2014 $'M $'M $'M $'M ____________ ___________ ___________ ___________ Financial assets: Available-for-sale securities (1) 13.1 13.1 - - Contingent consideration receivable (2) 15.9 - - 15.9 Foreign exchange contracts 12.6 - 12.6 - Financial liabilities: Foreign exchange contracts 7.8 - 7.8 - Contingent consideration payable (3) 1 629.9 - - 629.9 ____________ ___________ ___________ ___________ Available-for-sale securities are included within Investments in the consolidated balance sheet. (2) Contingent consideration receivable is included within Prepaid expenses and other current assets and Other non-current assets in the consolidated balance sheet . (3) Contingent consideration payable is included within Other current liabilities and O ther non- current liabilities in the consolidated balance sheet.
Assets Measured at Fair Value on a Recurring Basis Using Significant Unobervable Inputs (Level 3)	Contingent consideration receivable 2015 2014 $'M $'M ____________ ____________ Balance at January 1, 15.9 36.1 Initial recognition of contingent consideration receivable - 33.6 Loss recognized in the income statement (within discontinued operations) due to change in fair value during the period - (33.6) Gain/(loss) recognized in the income statement (within Gain on sale of product rights) due to change in fair value during the period 9.8 (4.1) Reclassification of amounts to Other receivables within Other current assets (12.1) (14.9) Amounts recorded to other comprehensive income (within foreign currency translation adjustments) 1.3 2.0 Balance at September 30, 14.9 19.1
Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobervable Inputs (Level 3)	Contingent consideration payable 2015 2014 $'M $'M ____________ ____________ Balance at January 1, 629.9 405.9 Initial recognition of contingent consideration payable 92.8 226.7 Change in fair value during the period with the corresponding adjustment recognized (within Integration and acquisition costs) in the income statement (196.5) 26.3 Reclassification of amounts to Other current liabilities (8.5) (12.4) Change in fair value during the period with corresponding adjustment to the associated intangible asset 0.2 1.8 Amounts recorded to other comprehensive income (within foreign currency translation adjustments) 2.7 (6.3) Balance at September 30, 520.6 642.0
Fair Value Inputs, Assets Quantitative Information Table	Financial assets: Fair Value at the Measurement Date At September 30, 2015 Fair value Valuation Technique Significant unobservable Inputs Range $'M ____________ ___________ ___________ ___________ Contingent consideration receivable ("CCR") 14.9 Income approach (probability weighted discounted cash flow) • Probability weightings applied to different sales scenarios • Future forecast consideration receivable based on contractual terms with purchaser • Assumed market participant discount rate • 10 to 70% • $26 million to $31 million • 8.7% ____________ ____________ ____________ ____________ Fair Value at the Measurement Date At September 30, 2015 Fair value Valuation Technique Significant unobservable Inputs Range $'M ____________ ___________ ___________ ___________ IPR&D intangible assets (SHP625 and SHP608) $120.4 Income approach (discounted cash flow) • Probability of regulatory approval being obtained • Expected commercial launch date • Assumed market participant discount rate • 5 to 33% • 2018 to 2021 • 9.7 to 10.7% ____________ ____________ ____________ ____________
Fair Value Inputs, Liabilities Quantitative Information Table	Financial liabilities: Fair Value at the Measurement Date At September 30, 2015 Fair value Valuation Technique Significant unobservable Inputs Range $'M ____________ ___________ ___________ ___________ Contingent consideration payable 520.6 Income approach (probability weighted discounted cash flow) • Cumulative probability of milestones being achieved • Assumed market participant discount rate • Periods in which milestones are expected to be achieved • Forecast quarterly royalties payable on net sales of relevant products • 4 to 85% • 1.2 to 12.4% • 2015 to 2029 • $0.2 to $6.6 million ____________ ____________ ____________ ____________

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Schedule of Calculation of Numerator and Denominator in Earnings Per Share	3 months to 3 months to 9 months to 9 months to September 30, September 30, September 30, September 30, 2015 2014 2015 2014 $’M $’M $’M $’M _________________ _________________ _________________ _________________ Income from continuing operations, net of taxes 477.1 515.8 1,054.1 1,297.2 Loss from discontinued operations 1 (24.3) (36.1) (31.3) (64.0) _________________ _________________ _________________ _________________ Numerator for basic and diluted earnings per share 452.8 479.7 1,022.8 1,233.2 _________________ _________________ _________________ _________________
Schedule of Weighted Average Number of Shares	Weighted average number of shares: Millions Millions Millions Millions _________________ _________________ _________________ _________________ Basic 1 590.9 587.6 590.2 586.1 Effect of dilutive shares: Share-based awards to employees 2 2.5 5.0 3.0 6.0 _________________ _________________ _________________ _________________ Diluted 593.4 592.6 593.2 592.1 _________________ _________________ _________________ _________________
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	3 months to 3 months to 9 months to 9 months to September 30, September 30, September 30, September 30, 2015 2014 2015 2014 No. of shares No. of shares No. of shares No. of shares Millions Millions Millions Millions _________________ _________________ _________________ _________________ Share-based awards to employees 1 3.9 0.3 3.3 0.3 _________________ _________________ _________________ _________________

Segmental Reporting (Tables)

Segmental Reporting (Tables)	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Schedule of Segment Revenue from Major Products	9 months to September 30, September 30, 2015 2014 $’M $’M ___________ ___________ VYVANSE 1,268.9 1,065.6 CINRYZE 474.4 360.6 LIALDA/MEZAVANT 483.0 449.1 ELAPRASE 405.5 449.5 FIRAZYR 319.8 262.3 REPLAGAL 325.5 380.7 PENTASA 232.7 213.8 VPRIV 256.2 273.0 ADDERALL XR 259.7 280.2 FOSRENOL 132.9 136.2 GATTEX/REVESTIVE 95.2 - XAGRID 75.0 82.1 INTUNIV 45.0 279.0 NATPARA 12.8 - Other product sales 89.6 97.6 ____________ ____________ Total product sales 4,476.2 4,329.7 ____________ ____________

Business Combinations (Details)

Business Combinations (Details) - USD ($) $ in Millions	Sep. 28, 2015	Jul. 30, 2015	Feb. 21, 2015	Feb. 18, 2015	Dec. 31, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2013
Non-current assets:
Goodwill					$ 2,474.9	$ 4,289.6	$ 2,373.7	$ 4,289.6	$ 2,373.7	$ 624.6
Pro Forma Information
Post acquisition unwind of inventory fair value adjustment included in consolidated statement of income								23	90.6
Integration and acquisition costs						89.9	$ 37.1	(46.8)	$ 155.8
NPS Pharma
Business Acquisition [Line Items]
Percentage of voting interests acquired			100.00%
Cash consideration paid			$ 5,219.6
Acquisition-date fair value of consideration			5,219.6
Current assets:
Cash and cash equivalents			41.6
Short term investments			67
Accounts receivable			33.4
Inventories			89.4
Deferred tax assets			156.3
Other current assets			11.1
Total current assets			398.8
Non-current assets:
Property, plant and equipment			4.8
Goodwill			1,679.4
Total assets			7,076
Current liabilities:
Accounts payable and other current liabilities			72.5
Short-term debt			27.4
Non-current liabilities:
Long term debt, less current portion			78.9
Deferred tax liabilities			1,673.1
Other non-current liabilities			4.5
Total liabilities			1,856.4
Fair value of identified assets acquired and liabilities assumed			5,219.6
Pro Forma Information
Post acquisition revenues included in consolidated statement of income						86.7		193.8
Post acquisition pre-tax losses included in consolidated statement of income						47.5		207.4
Post acquisition amortization of intangible assets included in consolidated statement of income						70.9		172.4
Post acquisition unwind of inventory fair value adjustment included in consolidated statement of income						6.7		21.7
Post acquisition integration costs included in consolidated statement of income						16.2		76.9
Integration and acquisition costs						$ 13.6		$ 131.2
NPS Pharma | Currently Marketed Products
Non-current assets:
Other intangible assets, net			$ 4,640
NPS Pharma | Currently Marketed Products | GATTEX/REVESTIVE
Pro Forma Information
Estimated useful life of intangible assets			24 years
NPS Pharma | Currently Marketed Products | NATPARA/NATPAR
Pro Forma Information
Estimated useful life of intangible assets			24 years
NPS Pharma | Other intangible assets
Non-current assets:
Other intangible assets, net			$ 353
Pro Forma Information
Weighted average amortization period of acquired amortizable intangible assets			4 years
NPS Pharma | Other intangible assets | Minimum
Pro Forma Information
Estimated useful life of intangible assets			4 years
NPS Pharma | Other intangible assets | Maximum
Pro Forma Information
Estimated useful life of intangible assets			5 years
Foresight
Business Acquisition [Line Items]
Percentage of voting interests acquired		100.00%
Cash consideration paid		$ 298.8
Current assets:
Total current assets		3
Non-current assets:
Goodwill		112.1
Non-current liabilities:
Total liabilities		116.3
Foresight | IPR&D | SHP640
Non-current assets:
Other intangible assets, net		$ 300
Solpharm
Business Acquisition [Line Items]
Percentage of voting interests acquired	100.00%
Cash consideration paid	$ 4.5
Acquisition-date fair value of consideration	5.2
Maximum amount of contingent cash consideration	3.1
Fair value of contingent consideration payable	0.7
Non-current assets:
Goodwill	4.4
Total assets	0.8
Non-current liabilities:
Fair value of identified assets acquired and liabilities assumed	$ 5.2
Meritage
Business Acquisition [Line Items]
Cash consideration paid				$ 74.8
Acquisition-date fair value of consideration				166.9
Maximum amount of contingent cash consideration				175
Fair value of contingent consideration payable				92.1
Current assets:
Total current assets				5.5
Non-current assets:
Goodwill				41.1
Non-current liabilities:
Total liabilities				54.7
Fair value of identified assets acquired and liabilities assumed				166.9
Meritage | IPR&D | SHP621
Non-current assets:
Other intangible assets, net				$ 175
Viropharma
Business Acquisition [Line Items]
Percentage of voting interests acquired					100.00%
Cash consideration paid					$ 3,997
Acquisition-date fair value of consideration					3,997
Expected operational synergies that will result from combining the commercial operations of Viropharma with those of Shire					400
Current assets:
Cash and cash equivalents					232.6
Short term investments					57.8
Accounts receivable					52.2
Inventories					203.6
Deferred tax assets					100.7
Purchased call option					346.7
Other current assets					50.9
Total current assets					1,044.5
Non-current assets:
Property, plant and equipment					24.7
Goodwill					1,655.5
Other non-current assets					10.4
Total assets					5,370.1
Current liabilities:
Accounts payable and other current liabilities					122.7
Short-term debt					551.4
Non-current liabilities:
Deferred tax liabilities					603.5
Other non-current liabilities					95.5
Total liabilities					1,373.1
Fair value of identified assets acquired and liabilities assumed					$ 3,997
Pro Forma Information
Discount rate used in determining fair value of acquired in process research and development, low rate					9.50%
Discount rate used in determining fair value of acquired in process research and development, high rate					10.00%
Viropharma | Currently Marketed Products
Non-current assets:
Other intangible assets, net					$ 2,320
Pro Forma Information
Weighted average amortization period of acquired amortizable intangible assets					22 years
Viropharma | Currently Marketed Products | Minimum
Pro Forma Information
Estimated useful life of intangible assets					10 years
Viropharma | Currently Marketed Products | Maximum
Pro Forma Information
Estimated useful life of intangible assets					23 years
Viropharma | IPR&D | MARIBAVIR
Non-current assets:
Other intangible assets, net					$ 315

Business Combinations (Pro Form

Business Combinations (Pro Forma Information) (Details) - NPS Pharma - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Pro Forma Information
Revenues	$ 4,730.9	$ 4,603.4
Net income from continuing operations	$ 1,005.6	$ 1,028.8
Net income from continuing operations per share - basic	$ 1.704	$ 1.755
Net income from continuing operations per share - diluted	$ 1.695	$ 1.738
Pro Forma Data Adjustments
An adjustment to increase amortization of intangible assets	$ (21.2)	$ (126.5)
Increase/(decrease) to net income to reflect acquisition related costs	105.2	(105.2)
Decrease to net income to reflect the additional interest expense		(16.7)
Increase/(decrease) to net income to reflect the fair value adjustment to acquisition date inventory.	$ 13.4	$ (13.4)

Reorganization Costs (Details)

Reorganization Costs (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)number	Sep. 30, 2014USD ($)
Restructuring and Related Cost [Line Items]
Reorganization costs	$ 31.1	$ 28.2	$ 59.6	$ 123.4
Reorganization cost incurred to date	305.1		305.1
Reorganizations costs, expected costs	85		85
Restructuring Reserve [Roll Forward]
Reorganization Reserve Opening liability			38
Amounts charged to re-organization	31.1	$ 28.2	59.6	$ 123.4
Reorganization liability, Paid and Utilized			(64.1)
Reorganization Reserve Closing liability	33.5		$ 33.5
Number of divisions | number			3
Involuntary termination benefits
Restructuring and Related Cost [Line Items]
Reorganization costs			$ 38.5
Restructuring Reserve [Roll Forward]
Reorganization Reserve Opening liability			38
Amounts charged to re-organization			38.5
Reorganization liability, Paid and Utilized			(53.7)
Reorganization Reserve Closing liability	22.8		22.8
Other reorganization costs
Restructuring and Related Cost [Line Items]
Reorganization costs			21.1
Restructuring Reserve [Roll Forward]
Reorganization Reserve Opening liability			0
Amounts charged to re-organization			21.1
Reorganization liability, Paid and Utilized			(10.4)
Reorganization Reserve Closing liability	$ 10.7		$ 10.7

Integration and acquisition c54

Integration and acquisition costs (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Business Acquisition [Line Items]
Integration and acquisition costs	$ 89.9	$ 37.1	$ (46.8)	$ 155.8
Contingent consideration payable, current (within other current liabilities)	111.7		111.7		$ 194.5
NPS Pharma
Business Acquisition [Line Items]
Integration and acquisition costs	13.6		131.2
Lumena
Business Acquisition [Line Items]
Contingent consideration payable, current (within other current liabilities)	90		90
Acquisition and Integration Costs, Gross Amount
Business Acquisition [Line Items]
Change in fair value of contingent consideration		4.9
Acquisition and Integration Costs, Gross Amount | Viropharma
Business Acquisition [Line Items]
Integration and acquisition costs		32.2		129.5
Acquisition and Integration Costs, Gross Amount | NPS Pharma, Viropharma and the proposed combination with Baxalta
Business Acquisition [Line Items]
Integration and acquisition costs	30.7		149.7
Acquisition and Integration Costs, Gross Amount | Lumena and Lotus Tissue Repair
Business Acquisition [Line Items]
Change in fair value of contingent consideration			(196.5)
Acquisition and Integration Costs, Gross Amount | SARcode and Ferrokin Bioscience, Inc
Business Acquisition [Line Items]
Change in fair value of contingent consideration				26.3
Acquisition and Integration Costs, Gross Amount | Lumena
Business Acquisition [Line Items]
Change in fair value of contingent consideration	59.2
Acquisition and Integration Costs, Net Amount
Business Acquisition [Line Items]
Integration and acquisition costs	$ 89.9	$ 37.1	$ (46.8)	$ 155.8

Accounts Receivable, Net (Detai

Accounts Receivable, Net (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Provision for discounts and doubtful accounts
As at January 1,	$ 48.5	$ 47.9
Provision charged to operations	293.8	228.1
Provision utilization	(286.6)	(229.8)
As at September 30,	55.7	$ 46.2
Accounts receivable, net	1,296		$ 1,035.1
Accounts receivable related to royalty income	$ 71.4		$ 59

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Schedule of Inventory
Finished goods	$ 161	$ 136
Work-in-progress	334.9	305.3
Raw materials	113	103.5
Total inventories	$ 608.9	$ 544.8

Results of discontinued opera57

Results of discontinued operations (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss from discontinued operations, net of taxes	$ (24.3)	$ (36.1)	$ (31.3)	$ (64)

Prepaid Expenses and Other Cu58

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid expenses	$ 50.6	$ 36.9
Income tax receivable	96.5	121.5
Value added taxes receivable	18.8	13.8
Other current assets	49.1	49.3
Prepaid expenses and other current assets, total	$ 215	$ 221.5

Goodwill (Details)

Goodwill (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Goodwill [Line Items]
Goodwill arising on business acquired	$ 1,837	$ 1,773.8
Goodwill [Roll Forward]
As at January 1,	2,474.9	624.6
Acquisition	1,837	1,773.8
Foreign currency translation	(22.3)	(24.7)
As at September 30,	$ 4,289.6	$ 2,373.7

Other Intangible Assets, Net (D

Other Intangible Assets, Net (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Jun. 30, 2015	Sep. 30, 2015		Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Intangible Assets (Excluding Goodwill) [Line Items]
Amortized intangible assets		$ 9,763.5			$ 4,846.9
Other intangible assets, gross		11,245.9			6,396.9
Less: Accumulated amortization		(1,795.3)	[1]		(1,462.5)
Other intangible assets, net		9,450.6		$ 5,227.4	4,934.4	$ 2,312.6
Other Disclosures
Acquisitions		5,473.7		3,332.8
Impairment charges		523.3		188
Change in fair value of contingent consideration		196.5		(26.3)
Estimates of Annual Amortization
2,015		470
2,016		470
2,017		470
2,018		470
2,019		470
Lumena and Lotus Tissue Repair
Other Disclosures
Change in fair value of contingent consideration		(203.4)
Currently Marketed Products
Intangible Assets (Excluding Goodwill) [Line Items]
Amortized intangible assets		9,388.5			4,816.9
Less: Accumulated amortization		(1,734.9)
Other intangible assets
Intangible Assets (Excluding Goodwill) [Line Items]
Amortized intangible assets		375	[2]		30
Less: Accumulated amortization		(60.4)
IPR&D
Intangible Assets (Excluding Goodwill) [Line Items]
Unamortized intangible assets		1,482.4			$ 1,550
IPR&D | Meritage and Foresight
Other Disclosures
Acquisitions		475
SHP602 IPR&D
Other Disclosures
Impairment charges				166
SHP613
Other Disclosures
Impairment charges				$ 22
Currently marketed products and royalty rights | NPS Pharma
Other Disclosures
Acquisitions		4,993
SHP625
Other Disclosures
Unamortized intangible assets, fair value		$ 120.4
Impairment charges	$ 346.6
SHP608
Other Disclosures
Impairment charges	$ 176.7
[1]	Comprising $1,734.9 million of accumulated amortization for intellectual property rights acquired for currently marketed products and $60.4 million for other intangible assets
[2]	Other intangible assets primarily comprises of royalty right assets acquired with NPS Pharma. Comprising $1,734.9 million of accumulated amortization for intellectual property rights acquired for currently marketed products and $60.4 million for other intangible assets.

Other Intangible Assets, Net (R

Other Intangible Assets, Net (Roll Forward) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Other Intangible Assets Roll Forward
As at January 1,	$ 4,934.4	$ 2,312.6
Acquisitions	5,473.7	3,332.8
Divestment on non-core product rights	0	(17.3)
Amortization charged	(352.3)	(181.9)
Impairment charges	(523.3)	(188)
Foreign currency translation	(81.9)	(30.8)
As at June 30,	$ 9,450.6	$ 5,227.4

Accounts Payable and Accrued 62

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Accounts Payable and Accrued Liabilities, Current [Line Items]
Trade accounts payable and accrued purchases	$ 313.2	$ 247.7
Accrued rebates - Medicaid	636.4	563.9
Accrued rebates - Managed care	336.5	318.2
Sales return reserve	141.8	131.7
Accrued bonuses	133.7	150.7
Accrued employee compensation and benefits payable	118.9	109.1
R&D accruals	71.5	88.3
Other accrued expenses	249.8	299.8
Accounts payable and accrued expenses, total	$ 2,001.8	$ 1,909.4

Other Current Liabilities (Deta

Other Current Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Other Liabilities, Current [Abstract]
Income taxes payable	$ 76	$ 16.2
Value added taxes	21.6	16.6
Contingent consideration payable	111.7	194.5
Other current liabilities	47.7	35.2
Other current liabilities, total	$ 257	$ 262.5

Borrowings (Details)

Borrowings (Details) $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)contract	Sep. 30, 2014USD ($)	Feb. 11, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 12, 2014USD ($)	Nov. 11, 2013USD ($)
Line of Credit Facility [Line Items]
Long-term borrowings	$ 70.7			$ 0
Short-term borrowings	2,005.7			850
Borrowing, Long-term and Short-term ,Combined Amount	2,076.4			850
Repayment of lines of credit	$ (2,486.1)	$ (1,461.8)
2013 Facilities Agreement
Line of Credit Facility [Line Items]
Facility agreement initiation date	Nov. 11, 2013
Facilitiy agreement total amount						$ 2,600
Number of term loan facilities | contract	2
Short-term borrowings	$ 0			850
Repayment of lines of credit	$ (350)
2015 Facility Agreement
Line of Credit Facility [Line Items]
Facility agreement initiation date	Jan. 11, 2015
Facilitiy agreement total amount	$ 750	$ 750	$ 850
Facility agreement expiration date	Jan. 10, 2016
Short-term borrowings	$ 750			0
Repayment of lines of credit	(100)
Secured Non-recourse Debts
Line of Credit Facility [Line Items]
Long-term borrowings	70.7			0
Short-term borrowings	10.7			0
Sensipar and Mimpara Debt, Amgen
Line of Credit Facility [Line Items]
Principal amount	145
Regpara Debt, DRI
Line of Credit Facility [Line Items]
Debt instrument, maximum obligation	96
PTH-184 Debt, DRI
Line of Credit Facility [Line Items]
Debt instrument, maximum obligation	$ 125
Term loan facility one | 2013 Facilities Agreement
Line of Credit Facility [Line Items]
Term loan facility						1,750
Term loan facilitly two | 2013 Facilities Agreement
Line of Credit Facility [Line Items]
Term loan facility						$ 850
Revolving Credit Facility
Line of Credit Facility [Line Items]
Facility agreement initiation date	Dec. 12, 2014
Facility agreement expiration date	Dec. 12, 2019
Swingline Facility	$ 250
Principal amount					$ 2,100
Short-term borrowings	$ 1,245			$ 0

Other Non-current Liabilities65

Other Non-current Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Other Liabilities, Noncurrent [Abstract]
Income taxes payable	$ 190.4	$ 199.2
Contingent consideration payable	408.9	435.4
Other non-current liabilities	140.5	102.1
Other noncurrent liabilities, total	$ 739.8	$ 736.7

Commitments and Contingencies66

Commitments and Contingencies (Leases, and LC and Guarantees ) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Future Minimum Lease Payments under Operating Leases
2,015	$ 13.5
2,016	44.7
2,017	31.6
2,018	25.3
2,019	20.9
2,020	20
Thereafter	125.8
Future minimum lease payments, total	281.8
Operating Leases, Rent Expense
Lease and rental expense	30.6	$ 29.3
Letters of credit and guarantees
Irrevocable standby letters of credit and guarantees	$ 49

Commitments and Contingencies67

Commitments and Contingencies (Collaborative Arrangements) (Details) - Out-licensing Arrangement - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Out-licensing arrangements
Milestone payments received	$ 12.6	$ 1
Other Revenues
Out-licensing arrangements
Milestone revenues recognized	1.5	3.6
Product Sales
Out-licensing arrangements
Milestone revenues recognized	37.2	$ 39.8
Development Milestone
Out-licensing arrangements
Maximum milestone payment receivable	39
Sales Milestone
Out-licensing arrangements
Maximum milestone payment receivable	$ 46

Commitments and Contingencies68

Commitments and Contingencies (Commitments and Loss Contingency) (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Legal Matters [Line Items]
Provisions for litigation loss, insurance claims and other disputes	$ 9.5	$ 16.9
Clinical Testing
Commitment [Line Items]
Commitment amount	454	382
Contract Manufacturing
Commitment [Line Items]
Commitment amount	321	384
Commitments expected to be paid in next year	71
Other Purchasing Commitment
Commitment [Line Items]
Commitment amount	352	265
Commitments expected to be paid in next year	331
Investment Commitment
Commitment [Line Items]
Commitment amount	49	67
Capital Commitment
Commitment [Line Items]
Commitment amount	$ 21	$ 3

Accumulated Other Comprehensi69

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
As at January 1,	$ (31.5)
Net current period other comprehensive (loss)/income	(123.6)
As at September 30,	(155.1)
Foreign currency translation adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
As at January 1,	(25.7)	$ 110.4
Other comprehensive (loss)/ income before reclassification		(75.9)
Gain transferred to the income statement (within Other income),net) on disposal of available-for-sale-securities		0
Net current period other comprehensive (loss)/income	(124.9)	(75.9)
As at September 30,	(150.6)	34.5
Unrealized holding gain/(loss) on available-for-sale securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
As at January 1,	(5.8)	(0.2)
Other comprehensive (loss)/ income before reclassification		5.6
Gain transferred to the income statement (within Other income),net) on disposal of available-for-sale-securities		(9.1)
Net current period other comprehensive (loss)/income	1.3	(3.5)
As at September 30,	(4.5)	(3.7)
Accumulated other comprehensive (loss)/income
Accumulated Other Comprehensive Income (Loss) [Line Items]
As at January 1,	(31.5)	110.2
Other comprehensive (loss)/ income before reclassification		(70.3)
Gain transferred to the income statement (within Other income),net) on disposal of available-for-sale-securities		(9.1)
Net current period other comprehensive (loss)/income	(123.6)	(79.4)
As at September 30,	$ (155.1)	$ 30.8

Financial Instruments (Interest

Financial Instruments (Interest Rate and Credit Risks) (Details) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2015USD ($)	Dec. 31, 2014USD ($)customer	Feb. 11, 2015USD ($)	Dec. 12, 2014USD ($)	Sep. 30, 2014USD ($)	Nov. 11, 2013USD ($)
Interest rate risk
Average interest rate received on cash and liquid investments	less than 1% per annum.
Line of Credit Facility [Line Items]
Interest rate risk exposure	The Company has evaluated the interest rate risk on the Credit lines, the RCF and the 2015 Facilitiy Agreement and considers the risks associated with floating interest rates on borrowings under its facilities as appropriate. A hypothetical one percentage point increase or decrease in the interest rates applicable to drawings under the Credit lines, the 2015 Facility Agreement and RCF at September 30, 2015 would increase interest expense by approximately $20 million per annum and would decrease the interest expense by approximately $4 million per annum.
Short-term borrowings	$ 2,005.7	$ 850
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of major external customers | customer		3
Customer concentration risk
Accounts, Notes, Loans and Financing Receivable [Line Items]
Concentration risk percentage		47.00%
Revolving Credit Facility
Line of Credit Facility [Line Items]
Short-term borrowings	1,245	$ 0
Principal amount				$ 2,100
2013 Facilities Agreement
Line of Credit Facility [Line Items]
Facilitiy agreement total amount						$ 2,600
Short-term borrowings	0	850
2015 Facility Agreement
Line of Credit Facility [Line Items]
Facilitiy agreement total amount	750		$ 850		$ 750
Short-term borrowings	750	$ 0
Government-owned or Supported Healthcare Providers | Italy
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable received	65.7
Government-owned or Supported Healthcare Providers | Spain
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable received	$ 80.6

Financial Instruments (Foreign

Financial Instruments (Foreign Exchange Risk and Its Classification on Balance Sheet) (Details) - Foreign Exchange Contract $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)contract	Dec. 31, 2014USD ($)
Derivatives, Fair Value
Net derivative fair value assets	$ 0.4
Net derivative fair value liabilities	7.7
Potential effect of rights of set off associated with the foreign exchange contracts	$ 1.4
Number of swap and forward foreign exchange contracts outstanding | contract	33
Swaps and forward contracts maturity	90 days
Prepaid expenses and other current assets
Derivatives, Fair Value
Assets	$ 1.8	$ 12.6
Other current liabilities
Derivatives, Fair Value
Liabilities	$ 9.1	$ 7.8

Financial Instruments (Foreig72

Financial Instruments (Foreign Exchange Risk and Its Effect on Income Statement) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Foreign Exchange Contract | Other income, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of net gains recognized in income	$ 12	$ 15.9

Fair Value Measurement (Assets

Fair Value Measurement (Assets and Liabilities That are Measured and Not Measured at Fair Value on a Recurring Basis) (Details) - Recurring Basis - USD ($) $ in Millions		Sep. 30, 2015	Dec. 31, 2014
Estimated fair value
Financial assets:
Available-for-sale securities	[1]	$ 14.4	$ 13.1
Contingent consideration receivable	[2]	14.9	15.9
Foreign exchange contracts, asset		1.8	12.6
Financial liabilities:
Foreign exchange contracts, liability		9.1	7.8
Contingent consideration payable	[3]	520.6	629.9
Level 1
Financial assets:
Available-for-sale securities	[1]	14.4	13.1
Contingent consideration receivable	[2]	0	0
Foreign exchange contracts, asset		0	0
Financial liabilities:
Foreign exchange contracts, liability		0	0
Contingent consideration payable	[3]	0	0
Level 2
Financial assets:
Available-for-sale securities	[1]	0	0
Contingent consideration receivable	[2]	0	0
Foreign exchange contracts, asset		1.8	12.6
Financial liabilities:
Foreign exchange contracts, liability		9.1	7.8
Contingent consideration payable	[3]	0	0
Level 3
Financial assets:
Available-for-sale securities	[1]	0	0
Contingent consideration receivable	[2]	14.9	15.9
Foreign exchange contracts, asset		0	0
Financial liabilities:
Foreign exchange contracts, liability		0	0
Contingent consideration payable	[3]	$ 520.6	$ 629.9
[1]	Available-for-sale securities are included within Investments in the consolidated balance sheet.
[2]	Contingent consideration receivable is included within Prepaid expenses and other current assets and Other non-current assets in the consolidated balance sheet.
[3]	Contingent consideration payable is included within Other current liabilities and Other non-current liabilities in the consolidated balance sheet.

Fair Value Measurement (Asset74

Fair Value Measurement (Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Change in the Fair Value of Contigent Consideration Receivable
Balance at beginning of period	$ 15.9	$ 36.1
Initial recognition of contingent consideration receivable	0	33.6
Gain/(loss) recognized in the income statement (within Gain on sale of product rights) due to change in fair value during the period	9.8	(4.1)
Reclassification of amounts to Other receivables within Other current assets	(12.1)	(14.9)
Amounts recorded to other comprehensive income (within foreign currency translation adjustments)	1.3	2
Balance at end of period	14.9	19.1
Change in the Fair Value of Contigent Consideration Payable
Balance at beginning of period	629.9	405.9
Initial recognition of contingent consideration payable	92.8	226.7
Change in fair value during the period with the corresponding adjustment recognized as a loss in the income statement (within Integration and acquisition costs)	(196.5)	26.3
Reclassification of amounts to Other current liabilities	(8.5)	(12.4)
Change in fair value during the period with corresponding adjustment to the associated intangible asset	0.2	1.8
Amounts recorded to other comprehensive income (within foreign currency translation adjustments)	2.7	(6.3)
Balance at end of period	520.6	642
Contingent consideration payable, current (within other current liabilities)	111.7		$ 194.5
Contingent consideration payable, non-current (within other non-current liabilities)	408.9		$ 435.4
Discontinued operations
Change in the Fair Value of Contigent Consideration Receivable
Gain/(loss) on change in the fair value of divestiture contingent consideration receivable	$ 0	$ (33.6)

Fair Value Measurement (Quantit

Fair Value Measurement (Quantitative Information About Recurring and Non-recurring Level 3 Fair Value Measurements) (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Jun. 30, 2015	Sep. 30, 2015	Sep. 30, 2014
Fair Value Inputs
Impairment of intangible assets		$ 523.3	$ 188
SHP602 IPR&D
Fair Value Inputs
Impairment of intangible assets			166
SHP613
Fair Value Inputs
Impairment of intangible assets			$ 22
SHP625
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
IPR&D intangible assets, fair value		$ 120.4
Fair Value Inputs
Impairment of intangible assets	$ 346.6
SHP608
Fair Value Inputs
Impairment of intangible assets	$ 176.7
Recurring Basis | Contingent Consideration Payable | Minimum
Fair Value Inputs
Assumed market participant discount rate		1.20%
Cumulative probability of milestones being achieved		4.00%
Periods in which milestones are expected to be achieved		2,015
Forecast quarterly royalties payable on net sales of relevant products		$ 0.2
Recurring Basis | Contingent Consideration Payable | Maximum
Fair Value Inputs
Assumed market participant discount rate		12.40%
Cumulative probability of milestones being achieved		85.00%
Periods in which milestones are expected to be achieved		2,029
Forecast quarterly royalties payable on net sales of relevant products		$ 6.6
Recurring Basis | Contingent Consideration Payable | Income approach (probability weighted discounted cash flow)
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Liabilities		520.6
Recurring Basis | Contingent Consideration Receivable | Income approach (probability weighted discounted cash flow)
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Assets		$ 14.9
Fair Value Inputs
Assumed market participant discount rate		8.70%
Recurring Basis | Contingent Consideration Receivable | Income approach (probability weighted discounted cash flow) | Minimum
Fair Value Inputs
Probability weightings applied to different sales scenarios		10.00%
Future forecast consideration receivable based on contractual terms with purchaser		$ 26
Recurring Basis | Contingent Consideration Receivable | Income approach (probability weighted discounted cash flow) | Maximum
Fair Value Inputs
Probability weightings applied to different sales scenarios		70.00%
Future forecast consideration receivable based on contractual terms with purchaser		$ 31
Nonrecurring Basis | SHP625
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
IPR&D intangible assets, fair value		120.4
Nonrecurring Basis | SHP625 and SHP608 combined
Fair Value Inputs
Impairment of intangible assets		$ 523.3
Nonrecurring Basis | Income approach (discounted cash flow) | Minimum | SHP625 and SHP608 combined
Fair Value Inputs
Assumed market participant discount rate		9.70%
Probability of regulatory approval being obtained		5.00%
Expected commercial launch date		2,018
Nonrecurring Basis | Income approach (discounted cash flow) | Maximum | SHP625 and SHP608 combined
Fair Value Inputs
Assumed market participant discount rate		10.70%
Probability of regulatory approval being obtained		33.00%
Expected commercial launch date		2,021

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) shares in Millions, $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Schedule of Calculation of Numerator and Denominator in Earnings Per Share
Income from continuing operations, net of taxes		$ 477.1	$ 515.8	$ 1,054.1	$ 1,297.2
Loss from discontinued operations, net of taxes		(24.3)	(36.1)	(31.3)	(64)
Net income		$ 452.8	$ 479.7	$ 1,022.8	$ 1,233.2
Schedule of Weighted Average Number of Shares
Basic (in shares)	[1]	590.9	587.6	590.2	586.1
Effect of dilutive shares:
Share based awards to employees (in shares)	[2]	2.5	5	3	6
Diluted (in shares)		593.4	592.6	593.2	592.1
Share Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	[3]	3.9	0.3	3.3	0.3
[1]	Excludes shares purchased by the EBT and presented by Shire as treasury stock
[2]	. Calculated using the treasury stock method
[3]	Certain stock options have been excluded from the calculation of diluted EPS because (a) their exercise prices exceeded Shire plc’s average share price during the calculation period or (b) the required performance conditions were not satisfied as at the balance sheet date.

Segmental Reporting (Revenue by

Segmental Reporting (Revenue by Product) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue from External Customer [Line Items]
Product sales	$ 1,576.8	$ 1,552	$ 4,476.2	$ 4,329.7
VYVANSE
Revenue from External Customer [Line Items]
Product sales			1,268.9	1,065.6
CINRYZE
Revenue from External Customer [Line Items]
Product sales			474.4	360.6
LIALDA/MEZAVANT
Revenue from External Customer [Line Items]
Product sales			483	449.1
ADDERALL XR
Revenue from External Customer [Line Items]
Product sales			259.7	280.2
INTUNIV
Revenue from External Customer [Line Items]
Product sales			45	279
PENTASA
Revenue from External Customer [Line Items]
Product sales			232.7	213.8
FOSRENOL
Revenue from External Customer [Line Items]
Product sales			132.9	136.2
XAGRID
Revenue from External Customer [Line Items]
Product sales			75	82.1
Other Products
Revenue from External Customer [Line Items]
Product sales			89.6	97.6
REPLAGAL
Revenue from External Customer [Line Items]
Product sales			325.5	380.7
ELAPRASE
Revenue from External Customer [Line Items]
Product sales			405.5	449.5
VPRIV
Revenue from External Customer [Line Items]
Product sales			256.2	273
FIRAZYR
Revenue from External Customer [Line Items]
Product sales			319.8	262.3
GATTEX/REVESTIVE
Revenue from External Customer [Line Items]
Product sales			95.2	0
NATPARA
Revenue from External Customer [Line Items]
Product sales			$ 12.8	$ 0

Taxation (Details)

Taxation (Details)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Effective Income Tax Rate Reconciliation
Effective rate of tax	(1.00%)	(5.00%)

Related parties (Details)

Related parties (Details) - ArmaGen $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)
Related Party Transaction [Line Items]
Amount paid for an equity stake and the license to develop and commercialize AGT-182	$ 2.5
Share of R&D credit recorded within R&D expense	7.2
Related parties, acrrued liabilities	$ 0.7
Percentage of equity stake	21.00%